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EGFR MODULATES MICRORNA MATURATION IN RESPONSE TO
HYPOXIA THROUGH PHOSPHORYLATION OF ARGONAUTE2

Jia Shen, Ph.D.*

Advisory Professor: Mien-Chie Hung, Ph.D.
MicroRNAs (miRNAs) are generated by two-step processing to yield small RNAs that
negatively regulate target gene expression at posttranscriptional level. Deregulation of
miRNAs has been linked to diverse pathological processes, including cancer. Recent studies
have also implicated miRNAs in regulatory roles to cope with a spectrum of stresses, such
as hypoxia, which is frequently encountered in the poorly angiogenic core of a solid tumor.
However, the upstream regulators of miRNA biogenesis machineries remain obscure,
raising the question of how tumor cells efficiently coordinate and impose specificity on
miRNA expression and function in response to stresses. Here, we show that EGFR, a wellcharacterized oncogene in human cancers, suppresses the maturation of specific tumorsuppressor-like miRNAs in response to hypoxic stress through phosphorylation of
Argonaute2 (Ago2) at Tyr393. The association between EGFR and Ago2 is enhanced by
hypoxia, leading to elevated Ago2-Y393 phosphorylation which in turn reduces the binding
of Dicer to Ago2 and inhibits miRNA processing from precursor miRNAs (pre-miRNAs) to
mature miRNAs. Interestingly, we also identify a long-loop structure in pre-miRNAs as a
critical

regulatory

element

in

phospho-Y393-Ago2-mediated

miRNA

maturation.

Furthermore, Ago2-Y393 phosphorylation mediates EGFR-enhanced cell survival and
invasiveness under hypoxia, and correlates with poorer overall survival in breast cancer
vi

patients. Our study reveals a previously unrecognized function of EGFR in miRNA
maturation and demonstrates how EGFR is likely to function as a regulator of Ago2 through
novel posttranslational modification. These findings suggest that modulation of miRNA
biogenesis is important for stress response in tumor cells and has potential clinical
implications (Shen et al., 2013).
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1.1 EGFR Activation and Endocytic Recycling
EGFR is a member of the ErbB family of receptor tyrosine kinases (RTK) with an
extracellular ligand-binding domain, a single hydrophobic transmembrane domain and a
cytoplasmic tyrosine kinase-containing domain (Olayioye et al., 2000). Binding of ligands,
including EGF, HB-EGF, TGFα and amphiregulin (AR), to the extracellular domain induces
the homo- or hetero-dimerization with other ErbB family members, and subsequent
enhancement of the catalytic activity of the intrinsic tyrosine kinase, which is considered to
be the “first-phase” activation (Koch et al., 1991). The “second-phase” activation takes place
after trans-autophosphorylation of specific tyrosine (Y) residues within the cytoplasmic tail,
creating mutiple docking sites to recruit signaling molecules containing Src homology 2
(SH2) domain or phosphortyrosine binding (PTB) domain, resulting in the activation of
multiple signal transduction pathways near the plasma membrane (Grant and Donaldson,
2009). Ligands binding also results in rapid internalization of activated receptors, either
through clathrin-dependent (CDE) or independent (CIE) pathway. Regardless of the mode of
entry, internalized cargo is usually delivered to the early endosome and then further sorted to
the late endosome and lysosome for degradation or routed to the trans-Golgi network (TGN)
or transited to the recycling endosomal carriers that back to the plasma membrane as an
equilibrium (Grant and Donaldson, 2009). All these events including dynamic network of
molecular interactions and post-translational modifications ultimately lead to EGFRmediated cell survival, proliferation, mobility and anti-apoptosis.

1.2 Sustained Signaling in Endosomes after Receptor Internalization
Numerous unique properties of endosomes, such as a relative small volume favoring
ligand-receptor association and maintenance of receptor activity, an enrichment in PtdIns3P
2

(phosphatidylinositol 3-phosphate) allowing the assembly of complexes involving PX
domain containing proteins, as well as the long residence time of activated receptors due to
slow endosomal sorting, indicates these subcellular locations can serve as important
signaling platforms after receptor internalization (Sorkin and von Zastrow, 2009). For
example, EGFR after entry into the cell still remain ligand bound, phosphorylated and active
in endosomes until the late stage of endosomal trafficking. Endocytosis has been proposed
to be necessary for the duration of the EGFR signaling as supported by the detection of all
the components of MAPK activation cascade in the endosomes (Sorkin and von Zastrow,
2009). Alternatively, distinct signaling may require receptor endocytosis and/or occur
exclusively on endosomal membranes.

1.3 EGFR and Cancer
Amplification of EGFR expression or up-regulation of EGFR signaling pathway has
been verified to be a common feature in a variety of human cancers including breast, glioma,
ovarian, non-small-cell lung, prostate, pancreatic, renal, and head and neck cancers (Abd ElRehim et al., 2004; Normanno et al., 2003). As a prognostic maker of advanced tumor stage,
EGFR expression level/ activation is correlated with reduced patient survival and high risk
of metastasis, therefore, it has been a central target for cancer therapy (Abd El-Rehim et al.,
2004). However, the causes of EGFR over-expression in human cancers remain not very
clear but at least involving gene amplification and mutation-induced constitutive activation.
Only a few cancer types such as glioblastoma and non-small-cell lung cancer has been
verified to display high incidence of EGFR mutation (20%-40%), while similar phenomena
are rarely observed in other cancers (Halatsch et al., 2006; Paez et al., 2004; Sharma et al.,
2007). Interestingly, recent studies found that the hypoxic tumor microenvironment can up3

regulate the translational level of EGFR (Franovic et al., 2007) and prolong its activation
though deregulation of Rab5-mediated EGFR endocytosis pathway (Wang et al., 2009).
Moreover, non-ligand stimulation, such as UV, IR, H2O2, and certain cytokines (like TNFalpha) have been shown to activate EGFR directly or indirectly, thereby enhance cancer cell
survival (Cao et al., 2008; Reynolds et al., 2003).

1.4 miRNA and Cancer
microRNAs (miRNAs) are abundant, short (20-25-nucleotide), single-stranded
regulatory RNA molecules, that collectively play critical roles in diverse developmental and
physiological processes in eukaryotes (Kim et al., 2009). The general defining features of
miRNAs are the cleavage of their precursor transcripts by one or more RNase III enzymes,
and the subsequent sorting of mature miRNAs into Argonaute proteins to form the RNAinduced

silencing

complex

(RISC),

a

ribonucleoprotein

complex

mediating

posttranscriptional gene silencing (Kim et al., 2009; Yang and Lai, 2011). As with other
classes of Argonaute-bound small RNAs, miRNAs serve as antisense guides to identify and
target messenger RNAs (mRNAs) via ~7 nt complementary base-pairing to the 5’ ends of
the mature miRNAs (preferentially nucleotides 2-8, the “Seed” of a miRNA). In
consequence, the targeted mRNAs are degraded, destabilized or translationally suppressed
by the Argonaute proteins (Kim et al., 2009; Meister, 2013). Computational and
experimental studies have provided multilayer supporting evidence for the broad impact of a
miRNA on hundreds of mRNA targets, such that a majority of the human transcripts are
predicted and proven to carry conserved binding sites for multiple miRNAs (Kim et al.,
2009). Not surprisingly, the deregulation of homeostatic control of miRNA biogenesis is
associated with multiple pathological diseases, including cancer.
4

Global down-regulation of mature miRNA level as well as up-regulation of specific
oncomiRs (miRNAs that are associated with oncogenic events) in certain tumor types has
become an important feature in cancer development and progression (Leung and Sharp,
2007; Lu et al., 2005; Nicoloso et al., 2009). The steady level of a mature miRNA is
determined by the rates of its transcription, biogenesis processing and turnover (Winter et al.,
2009). Transcriptional regulation, either activation or silencing, accounts for significant
portion of alterations in miRNA production (Choudhry and Catto, 2011), which however,
fail to explain another striking observation in cancer that compared with normal tissues the
primary transcripts of miRNAs (pri-miRNAs) are accumulated in tumors and the expression
of mature miRNAs is inconsistent with the level of corresponding miRNA precursors (premiRNAs) (Blenkiron et al., 2007; Lu et al., 2005; van Kouwenhove et al., 2011; Ventura and
Jacks, 2009). Indeed, miRNA maturation, as suggested by recent studies (Davis et al., 2008;
Mori et al., 2014; Shen et al., 2013; Suzuki et al., 2009), is subject to complex regulation
and defects during this process significantly contribute to tumorigenesis and cancer
progression. In contrast to the universal model of linear miRNA processing (Kim et al., 2009;
Winter et al., 2009), accumulating evidence, emerged in the past few years, leads to the
recognition of signaling-mediated control of miRNA processing, which opens a plethora of
new regulatory options to modulate individual or cluster of miRNAs differently. Such
regulations mainly rely on the intensive interplay between miRNA core machineries, RNAbinding proteins (RBPs) and signaling transducers or executors in response to external or
internal stimuli, and dynamically shape the extent of miRNA production to maintain the
robust gene expression under specific pathophysiological conditions (Davis et al., 2008;
Mori et al., 2014; Shen et al., 2013; Suzuki et al., 2009).
5

1.5 Classical Linear Processing of miRNAs
A canonical pathway driven by RNase III enzymes generates the majority of miRNAs
in metazoan (Kim, 2005; Kim et al., 2009). The biogenesis of miRNA starts with RNA
polymerase II-dependent (predominant) or RNA polymerase III-dependent transcription,
generating a long primary transcript (pri-miRNA) that contains a typical hairpin structure.
Like mRNAs, most pri-miRNAs are 5’ 7-methyl-guanosine (m7G) capped and 3’
polyadenylated

before

further

processing

mediated

by

nuclear

microprocessor

Drosha/DGCR8 heterodimer (Kim et al., 2009). DGCR8 (DiGeorge syndrome critical
region gene 8, also known as Pasha in invertebrates) functions as a molecular anchor that
recognizes pri-miRNA at stem-ssRNA junction and positions RNase III endonuclease
Drosha at correct catalytic sites to cleave ~11bp away from the junction, releasing a hairpinshaped pre-miRNA (Kim et al., 2009). Alternatively, miRNAs can be generated from short
intronic hairpins (named as mirtrons) which are excised by splicing and debranching to
mimic a regular pre-miRNA, and consequently bypass the first-step cleavage mediated by
Drosha/DGCR8 in the nucleus (Yang and Lai, 2011). The secondary structure (>14bp
dsRNA stem along with a short 3’ overhang) of the resulting miRNA precursor, ~55-70
nucleotide (nt) in length, is recognized by Exportin-5 (XPO5) in complex with Ran-GTP,
enabling its subsequent shuttling to cytoplasm via GTP hydrolysis (Kim et al., 2009; van
Kouwenhove et al., 2011). In the cytoplasm, the terminal loop of pre-miRNA is cleaved by
another double-stranded RNA (dsRNA)-specific RNase III Dicer in collaboration with
dsRNA-binding protein TRBP (TAR RNA-binding protein, also known as TARBP2, human
immunodeficiency virus transactivation responsive RNA-binding protein 2) or PACT (also
known as PRKRA, protein activator of PKR) (Kim et al., 2009; Winter et al., 2009). Both
6

5’-phosphorylated end and 3’ overhang of the pre-miRNA are anchored by the PAZ domain
of Dicer, while the dsRNA stem is placed along the positively charged protein extension to
reach the catalytic center of Dicer. This spatial arrangement determines the precise cleavage
site in miRNA precursor that is a fixed distance, ~22nt, either from the 3’ end (3’ counting
model) (Kim et al., 2009) or the 5’ end of the terminus (5’ counting rule) (Park et al., 2011).
TRBP, as a cofactor, facilitates Dicer-mediated cleavage through direct binding with the
pre-miRNA via its two dsRNA-binding domains (dsRBDs) and concomitantly enhances the
stability of Dicer-RNA complex using its third dsRBD (Chendrimada et al., 2005; Daniels et
al., 2009). Both TRBP and PACT, though not essential for miRNA maturation, participate in
the recruitment of Argonaute2 (Ago2) to Dicer, forming the RISC loading complex (RLC)
for efficient miRNA processing and subsequent RISC assembly (Winter et al., 2009).
Notably, in vitro reconstitution of RISC loading and activation is achieved by Dicer, TRBP
and Ago2 alone (Maniataki and Mourelatos, 2005). Exported miRNA precursors only join
and fuel the RLC after the formation of this ternary complex, a process independent of ATP
hydrolysis (Maniataki and Mourelatos, 2005). After cleavage, miRNA duplex is further
unwound based on the rule of asymmetric separation (strand with less stable base pairs at its
5’ end in dsRNA intermediate is selected and loaded into RISC) (Kim et al., 2009).
Although it remains unclear how the RLC precisely coordinates the sequential events such
as precursor loading, cleavage, duplex unwinding, and the subsequent cargo loading into
RISC, evidence suggests that the stable end of the Dicer-cleaved RNA duplex is bound to
TRBP in RLC, whereas the other end interacts with Ago2 (Kim et al., 2009; Meister, 2013),
resulting in the functional guide strand (mature miRNA) that is complementary to its mRNA
targets and the passenger strand which is frequently fast degraded. After dsRNA unwinding,
7

Ago2 (and possibly other AGO proteins) loaded with mature miRNA dissociates with Dicer
and TRBP to form the active RISC for target gene silencing (Meister, 2013). Argonautes are
highly specialized binding modules that function as regulators in miRNA maturation and
also executors in small RNA-mediated gene silencing (Hutvagner and Simard, 2008; Winter
et al., 2009). All the AGO proteins are characterized by evolutionarily conserved MID and
PAZ domains involved in RNA binding and an RNase H-like PIWI domain for
endonuclease activity (Hutvagner and Simard, 2008; Meister, 2013). In mammals, there are
four AGO proteins (Ago1-4) but only Ago2 is catalytically active and could function as an
endonuclease (Hutvagner and Simard, 2008). Structural studies suggest that the 3’ end of a
mature miRNA is stably bound by the PAZ domain while the 5’ phosphate group of the
small RNA is anchored by the MID domain (Meister, 2013). Proper small RNA loading and
duplex unwinding are further assisted by the N-terminal domain in Argonautes (Kwak and
Tomari, 2012). In some occasions, a processing intermediate is generated by Ago2dependent cleavage of pre-miRNA to facilitate miRNA maturation and removal of the
passenger strand. Additionally, AGO proteins are capable to stabilize mature miRNAs via
direct binding and post-transcriptionally regulate miRNA abundance independent of
endonuclease activity (Diederichs and Haber, 2007). Recently, a Dicer-independent miRNA
biogenesis pathway (as exemplified by pre-miR-451) that utilizes Ago2 slicer catalytic
activity for processing was identified (Cheloufi et al., 2010; Cifuentes et al., 2010). The
short stem region of pre-miR-451 cannot be recognized by Dicer but is trimmed by Ago2 to
generate the corresponding mature miRNA (Cheloufi et al., 2010). However, the extent to
which such phenomena (processing that completely depends on Ago2) occur is still unclear
and need further investigations.
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1.6 Signaling-Mediated Regulation of miRNA Processing
miRNAs are often deregulated in cancer (Leung and Sharp, 2007; Lu et al., 2005;
Nicoloso et al., 2009). In contrast to the defined oncogene or tumor suppressor, miRNA
alteration is rarely caused by gene amplification or disruption (Yang and Lai, 2011). Instead,
impairment of crucial steps in the process of miRNA maturation, either in the nucleus or in
the cytoplasm, could be the underlying main causes that significantly contribute to the
development of malignancies. Notably, recent studies (Cheng et al., 2014; Davis et al., 2008;
Mori et al., 2014; Shen et al., 2013; Suzuki et al., 2009; Yamagata et al., 2009) demonstrate
the intensive crosstalk between signaling pathways and miRNA processing, suggesting that
the biogenesis of miRNA is under tight signaling control and has become an important part
of the large regulatory networks.

1.6.1 Regulation of miRNA Processing in the Nucleus
The stability of the nuclear microprocessor is self-controlled by the cross-regulation
between Drosha and DGCR8 (Kim, 2005; Kim et al., 2009), while the processing efficacy of
pri-miRNA is further tuned by other accessory RNA-binding proteins, such as DDX5 (also
known as p68) and DDX17 (also known as p72) (Kim et al., 2009; van Kouwenhove et al.,
2011). Both DDX5 and DDX17 directly interact with Drosha/DGCR8 to form a larger
nuclear processing complex and function as restricted promoting factors that are specifically
required for efficient processing of a subset of pri-miRNAs (Fuller-Pace and Moore, 2011;
Slezak-Prochazka et al., 2010; van Kouwenhove et al., 2011). Intriguingly, DDX5 and
DDX17 also serve as signal mediators that bridge the nuclear microprocessor activity with
other signaling pathways under varying circumstances. In response to estrogen (E2),
activated estrogen receptor (ERα) together with E2 attenuates the processing of subclass pri9

miRNAs into precursors through direct interaction with DDX5 and DDX17. In consequence,
the RNA-binding subunits in Drosha complex is competitively blocked by the cognate
nuclear receptor of steroid hormones, resulting in the suppression of miRNA processing and
subsequently the stabilization of ERα target genes (Yamagata et al., 2009). In the context of
DNA damage, tumor suppressor p53 binds with DDX5 to enhance Drosha/DGCR8mediated processing of a cluster of miRNAs which exert growth suppressive functions.
Transcriptionally inactive p53 mutants, frequently identified in human tumors, interfere with
the functional assembly between Drosha complex and DDX5, which in consequence hinder
the nuclear processing of those miRNAs (Suzuki et al., 2009). Similar case is also illustrated
by the SMAD signal transducers in response to transforming growth factor-β (TGFβ) and
bone morphogenetic protein (BMP) growth factor (Davis et al., 2008). The SMADs, in
complex with the microprocessor component DDX5, promote the nuclear processing of
miRNA (specifically, miR-21, a well-characterized oncomiR in cancer) via a consensus
binding sequence (similar to the known SMAD-response element in gene promoters) in
dsRNA stem of the pri-miRNA. More recently, cell-density-dependent control of miRNA
biogenesis was uncovered and tightly linked to tumor-suppressive Hippo signaling pathway
via its downstream target YAP (Yes-associated protein 1, oncogene, inactivated by Hippo
signaling) (Mori et al., 2014). At low cell density, DDX17 (p72) is bound and sequestered
by nuclear YAP, which in turn dissociates DDX17 from the nuclear microprocessor
complex and hence decreases the processing efficacy of a group of miRNAs in the nucleus.
When reach high cell density, YAP is restricted in cytoplasm by activated Hippo signaling.
DDX17, in that scenario, associates with Drosha/DGCR8 complex and enhances miRNA
processing through binding to a specific sequence motif in the 3’ flanking region of a pri10

miRNA. Notably, DDX5 and DDX17 are also known to function as transcription regulators
(Fuller-Pace and Moore, 2011), either coactivators (predominant) or corepressors. For
instance, both DDX5 and DDX17 serve as coactivators of ERα, β-catenin and MyoD
through facilitating the recruitment of other components of transcriptional machinery to the
target gene promoters (Caretti et al., 2006; Endoh et al., 1999; Metivier et al., 2003; Yang et
al., 2006). More specifically, DDX5 is a coactivator of p53, AR, RunX2 and the p50 subunit
of NF-kB via direct interaction with those important transcription factors (Bates et al., 2005;
Clark et al., 2008; Jensen et al., 2008; Wang et al., 2012), while DDX17 coactivates MDM2
transcription, in both p53-dependent and independent manor (Fuller-Pace and Moore, 2011).
The precise roles of DDX5 and DDX17 in cancer development remain controversial. Ddx5deficient and Ddx17-deficient mouse embryonic fibroblasts (MEFs) are characterized by
reduced cell growth and enhanced apoptosis (Fukuda et al., 2007). Consistently, silencing
both DDX5 and DDX17 inhibits cell proliferation (Jalal et al., 2007), whereas
overexpression of DDX5 facilitates cell growth and promotes epithelial-to-mesenchymal
(EMT) transition upon growth factor stimulation (Yang et al., 2006). However, higher
expression of DDX17 in breast tumors associates with a favorable prognosis with
significantly increased disease-free and overall survival (Wortham et al., 2009). DDX5, in
contrast, is often overexpressed and frequently gene-amplified, with rare mutations, in breast
invasive carcinomas (8.6% amplification vs. 0.3% mutations, from the Cancer Genome
Atlas). Different roles of DDX5 and DDX17, in terms of prognosis, are also reported in
other cancer types, including head and neck, prostate and colorectal cancers (Causevic et al.,
2001; Clark et al., 2008; Haines et al., 1993). Possibly, their biological functions, as tumor
promoter or suppressor, are cell-type-dependent or restricted by certain genetic background.
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One thing interesting is that the binding partners of DDX5/DDX17, involved in
transcriptional modulation or miRNA processing, are largely overlapped, suggesting an
intimate collaboration in gene expression between transcriptional and posttranscriptional
regulations. Nonetheless, the specific function of DDX5 and DDX17, as components of
Drosha/DGCR8 complex, in cancer development is still unclear and need to be further
elucidated by systemic investigation of their target miRNAs.
Drosha/DGCR8-mediated miRNA processing is also subject to other regulation
mechanisms, including additional binding partners with microprocessor and multiple RNAbinding proteins that can recognize and directly interact with subclass pri-miRNAs (van
Kouwenhove et al., 2011). DGCR8 is a heme-binding protein. Heme promotes DGCR8
dimer to trimerize upon loading pri-miRNAs and subsequently facilitates pri-miRNA
cleavage via blocking the auto-inhibition domain in DGCR8 (Faller et al., 2007). MeCP2
(methyl-CpG binding protein2), a transcriptional repressor that is critical for proper
development and function in central nerve system, is another direct interaction partner with
DGCR8 (Cheng et al., 2014). MeCP2 binds to DGCR8 via its C-terminal domain and
interferes with the assembly of Drosha/DGCR8 complex. Interestingly, the association
between MeCP2 and DGCR8 is tightly regulated by the phosphorylation status of MeCP2 at
Ser80, which is constantly phosphorylated under resting stage but rapidly dephosphorylated
upon neuronal activity. As a protein-binding switch, phosphorylation of Ser80 in MeCP2
“opens” its conformation to interact with DGCR8 and thus inhibits miRNA maturation
through dissembling the microprocessor complex (Cheng et al., 2014). Another essential
regulatory module in nuclear miRNA processing belongs to the huge family of RNAbinding proteins (RBPs). RBPs, including DDX5 and DDX17, are key players in miRNA
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biogenesis as they control multistep processing as well as the localization, degradation and
functional activity of miRNAs. Most RBPs recognize specific sequence motifs or secondary
structures via their RNA-binding domains. For instance, mRNA splicing factor SRSF1 (also
known as SF2/ASF) binds to the stem region of specific pri-miRNAs (Wu et al., 2010),
while hnRNP A1 (heterogeneous nuclear ribonucleoprotein A1) and KSRP (KH-type
splicing regulatory protein, also known as KHSRP) recognize the terminal loop of subclass
pri-miRNAs (Guil and Caceres, 2007; Trabucchi et al., 2009). Regardless of that, all of the
three facilitate the cleavage by Drosha/DGCR8 upon anchoring the pri-miRNAs (except for
pri-let-7 which is inhibited by hnRNP A1) (Michlewski and Caceres, 2010). In contrast,
Lin28, an RBP exclusively expressed in undifferentiated stage, specifically binds to the
terminal loop of pri-let-7, thereby inhibits its processing in the nucleus (Rybak et al., 2008).
Similarly, NF90 and NF45, two known components of the larger Drosha/DGCR8 complex,
suppress Drosha-mediated cleavage via competitive loading with certain pri-miRNAs
(Sakamoto et al., 2009). The RNA targets of those RBPs are unavoidably overlapped,
raising the question that how upstream signals efficiently coordinate their RNAinteractomes, either spatially or temporally, to influence the process of specific miRNA
maturation in the nucleus. Rarely, DNA-binding protein, as exemplified by BRCA1 (the
tumor suppressor breast cancer1), also promotes the processing of subclass miRNAs via
direct interaction with their primary transcripts (Kawai and Amano, 2012). BRCA1
associates with super microprocessor complex as well as other additional processing
modulators, including Smad3, p53 and DHX9. The DNA-binding domain is required for
BRCA1 anchoring to the branched structure at the root of a hairpin in the pri-miRNAs,
similar to its DNA-binding preference (Kawai and Amano, 2012). Nonetheless, the
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regulatory function of BRCA1 in miRNA processing was examined in the absence of DNA
damage. It remains unknown whether BRCA1 functions the same in response to DNA
damage, and if so, how important those BRCA1-regulated miRNAs are in the process of
DNA repair.

1.6.2 Regulation of miRNA Shuttling
Genetic mutations in Exportin-5 were identified both in colon cancer cell lines and in
human colorectal tumors (Melo et al., 2010). A frame-shift mutation in XPO5 creates a
premature termination codon, resulting in a truncated protein that lacks a small region in the
C-terminus. Interestingly, the Exportin-5 mutant fails to form a proper XPO5/Ran-GTP/premiRNA ternary complex due to its reduced binding and/or recognition capability with the
cargo, pre-miRNA. In consequence, miRNA precursors after the first-step processing are
trapped in nucleus, leading to the reduced expression of mature miRNAs (Melo et al., 2010).
However, genetic alterations of XPO5 are heterogeneous in human cancers, and in general,
low-frequency events. XPO5 is amplified without mutations in ovarian serous
cystadenocarcinoma and glioblastoma (with 2.8%, and 1.5% incidence respectively, from
the Cancer Genome Atlas), while gene amplification and mutations of XPO5 coexist in
other cancer types, including breast, prostate and colon cancers (1.4% amplification vs. 0.5%
mutation in colorectal carcinomas, from the Cancer Genome Atlas). Notably, XPO5 frameshift mutations are present in 22.8% of human primary colorectal tumors with microsatellite
instability (Melo et al., 2010), suggesting that the genetic control of miRNA exportation is
critically important in this subpopulation of patients. The upstream signaling regulators for
miRNA exportation, either via Exportin-5 or Ran-GTP, are not yet identified so far.
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1.6.3 Regulation of miRNA processing in the cytoplasm
As a haploinsufficient tumor suppressor, mutations and heterozygous deletion of
DICER1 are frequently observed in various human tumors (Hill et al., 2009; Kumar et al.,
2009; Lambertz et al., 2010). The steady level of Dicer is positively regulated by TRBP as a
complex (Chendrimada et al., 2005), while the expression of Dicer is further controlled by
multiple miRNAs via its super long 3’UTR. Both Let-7 and miR-103/107 reduce Dicer
protein level through direct interaction with multiple binding sequences existing in 3’UTR
or the coding region of DICER mRNA (Martello et al., 2010; Tokumaru et al., 2008). High
expression of miR-103/107 attenuates Dicer-mediated miRNA processing, resulting in
general down-regulation of mature miRNAs. Subsequently, blocked biogenesis, specifically
the miR-200 family, promotes the epithelial-to-mesenchymal transition (EMT) in breast
cancer cell lines (Martello et al., 2010). More recently, Dicer was found to be SUMOylated
after short-exposure to cigarette smoke in alveolar macrophages (Gross et al., 2014).
However, the detailed mechanistic nature as well as the potential functional importance of
this modification is still unclear.
TRBP, a key component of the RISC-loading complex, is also susceptible to genetic
disruptions. Frame-shift mutants of TRBP, with reduced binding affinity with Dicer, were
identified in human colorectal tumors with microsatellite instability (Garre et al., 2010;
Melo et al., 2009). In general, the mutation rate of TRBP is very low (for instance, less than
1.5% in colorectal adenocarcinoma, from the Cancer Genome Atlas), except for adenoid
cystic carcinoma from which TRBP is deleted in 15% of the patients (from the Cancer
Genome Atlas). The underlining mechanisms of genetic deletion as well as the
corresponding functional consequences in those tumors remain unknown and need to be
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investigated. Interestingly, TRBP is rapidly phosphorylated by Erk (mitogen-activated
protein kinase 1) at S142, S152, S283 and S286 in response to growth factor stimulation
(Paroo et al., 2009). Phosphorylation of TRBP stabilizes both TRBP and Dicer, resulting in
enhanced miRNA processing in the cytoplasm. Of note, the expression of let-7 tumor
suppressor family is down-regulated in the context of TRBP phosphorylation (Paroo et al.,
2009), raising the question that how phosphorylated TRBP specifically inhibits the
maturation of let-7 miRNAs.
Not surprisingly, the biogenesis control of let-7 family is concomitantly targeted by
multiple pathways. In the cytoplasm, pre-let-7 bound by Lin28 is frequently uridylated by
TUT4 (also known as ZCCHC11) at the 3’ terminus, which consequently inhibits Dicer
cleavage for maturation and tags the precursor RNA for rapid degradation by nucleases (Heo
et al., 2009). In contrast, KSRP anchors to the conserved region of let-7 terminal loop and
that of the other miRNAs, thereby facilitates their maturation through interaction with Dicer
in the cytoplasm (Trabucchi et al., 2009). The loop structure of pre-miRNA is also
recognized by the endo-RNase MCPIP1 (monocyte chemoattractant protein induced protein
1, also known as ZC3H12A), which antagonizes Dicer to bind and cleave the loop from the
target miRNA precursors for degradation (Suzuki et al., 2011). Notably, both Lin28 and
MCPIP1 are up-regulated in response to inflammation (Iliopoulos et al., 2010; Suzuki et al.,
2011), while KSRP is phosphorylated and functionally inhibited by p38 MAP kinase and the
PI3K-AKT pathway (Briata et al., 2005; Gherzi et al., 2006), suggesting that most regulators
in miRNA biogenesis are under intensive control of signaling networks.
Another essential regulatory module in miRNA biogenesis belongs to the Argonautes.
Particularly, Ago2, a regulator in miRNA maturation and an executer in miRNA-mediated
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gene silencing, is under tight regulation in response to varies signals. Ago2 is stabilized and
functionally potentiated by hydroxylation at proline 700 mediated by type I collagen propyl4-hydroxylase (C-P4H(I)) (Qi et al., 2008; Wu et al., 2011). During the undifferentiated cell
stage (such as embryonic stem cells and embryocarcinoma cell lines), Ago2 is
polyubiquitylated by the E3 ligase mLin-41 (mouse homologue of Lin-41, also known as
TRIM71), and subsequently undergoes proteasome-mediated degradation (Rybak et al.,
2009). Of note, Lin-41, similar to Lin-28, is targeted and suppressed by let-7, thereby is
silenced in differentiated cells. So far, the specific E3 ligase that responsible for Ago2
ubiquitination in somatic cells has not been identified yet. Nonetheless, miRNA-loading-free
Dicer and Ago2 are marked by polyubiquitination which serves as a sign for degradation
through recruiting the selective autophagy receptor NDP52 (Gibbings et al., 2012). In the
context of cellular stress, Ago2 is modified by pADPr (poly ADP-ribosylation) and in
consequence relieves miRNA-mediated gene silencing (Leung et al., 2011). The level of
mature miRNAs under that condition was not examined in the study; therefore, it remains
unknown whether miRNA processing is similarly affected by this modification. Besides that,
the functionality of Ago2 in miRNA maturation is also modulated by its binding partner
HSP90 (heat shock protein 90) which hydrolyses ATP to facilitate the loading of RNA
duplex from Dicer into Ago2 (Iki et al., 2010; Iwasaki et al., 2010; Johnston et al., 2010).
Like most signaling mediators, Ago2 receives signals (phosphorylations) in response
to external or internal stimuli and transmits new signals (functional changes) to orchestrate
gene expression programs via miRNA regulation. Human Ago2 is phosphorylated at Ser387
by both p38 MAP kinase and the proto-oncogene Akt3 (Horman et al., 2013; Zeng et al.,
2008). S387-phosphorylation of Ago2 facilitates its localization to the cytoplasmic
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processing bodies (P bodies, intracellular places for mRNA turnover and translational
repression) and enhances its binding with GW182, a key component of RISC. As a net result,
Ago2-mediated translational repression is strengthened while its cleavage activity towards
mRNAs is controversially reduced (Horman et al., 2013). Mass spectrometry analysis
indicates that Ago2 is tyrosine phosphorylated at both Y393 and Y529. Phosphorylation of
Ago2 at Y529 reduces its small RNA binding capability in vitro (Rudel et al., 2011).
However, neither the kinases that are responsible for Ago2 tyrosine phosphorylation nor the
functional relevance of Y393 phosphorylation had been demonstrated until our recent work
was published in Nature.
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2.1 Cell Culture and Treatment
Human lung cancer cell line (A-549), human hepatoma cell line (Hep3B), human
embryonic kidney cell line (293T), human cervical cancer cell line (HeLa), human
mammary epithelial cell lines (MCF-10A and MCF-12A), and human breast cancer cell line
(BT-549) were obtained from ATCC. Breast cancer cell line (MDA-MB-231) was gift from
Dr. Patricia S. Steeg (National Cancer Institute). RCC4 cell line was kindly given by Dr.
Thai Huu Ho from MD Anderson Cancer Center. MCF-10A and MCF-12A cells were
grown(Debnath et al., 2003) in DMEM-F12 medium supplemented with 5% horse serum,
epidermal growth factor (EGF, 20 ng/ml), insulin (10 µg/ml), cholera toxin (100 ng/ml) and
hydrocortisone (0.5 µg/ml). Other cells were grown in DMEM-F12 medium supplemented
with 10% fetal bovine serum (FBS). HeLa TetOff-inducible advanced cell line were
purchased from Clontech and maintained in DMEM-F12 medium supplemented with 10%
Tet-System Approved FBS (Clontech) with both G418 (500 µg/ml) and doxycycline (100
ng/ml). For HeLa TetOff-inducible EGFR and Ago2 stable clones (Plvx-Tight-Vector
Control; WT and KD EGFR; WT and Y393F Ago2), cells were maintained in DMEM-F12
medium supplemented with 10% Tet-System Approved FBS (Clontech) with G418 (500
µg/ml), Puromycin (1 µg/ml) and doxycycline (500 ng/ml). The expression of GOI (EGFR
or Ago2) was induced after doxycycline removal in accordance with manufacturer’s
instructions. For hypoxia treatment, cells were seeded at same density in DMEM-F12
medium supplemented with 10% FBS and allowed 4 to 6 hours for adherence in regular cell
culture incubator before moving into the hypoxia chamber (INVIV O2 400, setting as 1% O2
and 5% CO2, RUSKINN). HeLa TetOff-inducible stable clones after doxycycline removal
were seeded at same density and cultured in regular cell incubator for O/N before moving
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into the hypoxia chamber. All cell samples were lysed inside of the hypoxia chamber for
both IP-WB and RNA extraction. For induction of oxidative stress, cells cultured in DMEMF12 supplemented with 10% FBS were treated with 500 µM H2O2 (Sigma) or 500 µM
sodium arsenite (Sigma) for indicated time before collection. Epidermal growth factor (EGF)
and Transforming Growth Factor-α (human TGF-α, Sigma) were prepared according to the
manufacturers' instructions. Cells were serum-starved and then treated with EGF (20 ng/ml)
or TGF-α (10 ng/ml) for indicated time before collection. To induce DNA damage, cells
cultured in normal medium were treated with Cisplatin (50 µM) or Etoposide (50 µM) for
indicated time before collection. 50 nM AG1478 (Calbiochem) and 1 µM Iressa (Gefitinib)
were used to inhibit EGFR kinase activity. 1 µM FM19G11 (Sigma) and 6 µM CAY10585
(Cayman Chemicals) were used to inhibit the transcriptional activity of HIF1/2α.

2.2 Antibodies and Peptides
For WB: Flag epitope tag M2 (1: 2,000, Sigma); Flag tag antibody #2368 (1:1,000,
Cell Signaling); Anti-HA, 12CA5, (1:2000, Roche Molecular Biochemicals); c-myc
antibody 9E10 (1:2,000, Roche Molecular Biochemicals); HIF1α, clone54 (1:500, BD
Biosciences); HIF2α, D9E3 #7096 (1:500, Cell Signaling); VHL, PA5-17477, (1:500,
Thermo Scientific Pierce Antibodies); antibody against phosphotyrosine, 4G10 (1:3,000,
Millipore); Dcp1a, ab47811 (1:1,000, Abcam); Ago2/EIF2C2, ab32381 (1:1,000, Abcam);
Argonaute2, C34C6 (1:1,000, Cell Signaling); Anti-AGO2, 11A9 (1:1,000, Sigma); Dicer,
H-212 (1:200, Santa Cruz Biotechnology); Dicer, #3363 (1:500, Cell Signaling); AntiLAMP1, CD107a (1:1,000, Millipore); GW182, A302-329A (1:1,000, Bethyl Laboratories);
Alix, 3A9 (1:1,000, Cell Signaling); TRBP, 46D1 (1:1,1000, Abnova); EEA1, clone14
(1:1,000, BD Biosciences); Hrs, ab56468 (1:1,1000, Abcam); EGFR, sc-03 (1:1,1000, Santa
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Cruz Biotechnology); LOX, NB100-2527 (1: 1000, Novus Biologicals); p-Y1086-EGFR,
#2220, (1:1,000, Cell Signaling); Grb2, 610112, (1:1000, BD Biosciences); p-Y393-AGO2
(1:1,500, homemade); α-tubulin (1:5,000, Sigma); β-actin, AC-74 (1:2,000, Sigma);
LaminB1, 4B10, (1:500, Novus Biologicals). For IP: Flag epitope tag M2 (Sigma); EGFR,
ab-13 (Thermo Scientific). For IF: GW182, 4B6 (1:50, Abcam); Anti-AGO2, 11A9 (1:200,
Sigma); Dcp1a, ab47811 (1:200, Abcam); EGFR, sc-03 (1:150, Santa Cruz Biotechnology);
EGFR, ab-13 (1:250, Thermo Scientific); EGFR, ICR10 (1:50, Abcam); Anti-HIF1α, clone
EP1215Y (1:200, Millipore); p-Y393-AGO2 (1:2,000, homemade). For IHC: Anti-HIF1α,
clone EP1215Y (1:400, Millipore); Anti-HIF2α, NB100-122, (1:300, Novus Biologicals);
EGF Receptor, D38B1, (1:100, Cell Signaling); p-Y393-AGO2 (1:3,200, homemade). The
following peptides were chemically synthesized for antibody production in mice (Lifetein
Conc.),

Elisa

verification

(Lifetein

Conc.)

and

peptide

competition

assay

in

immunohistochemistry (IHC). Phospho-Y393-Ago2-peptide: NTDP-pY-VREFG; Nonphospho-Y393-Ago2-peptide:

NTDP-Y-VREFG.

Random

chosen

phospho-tyrosine

peptides (EGFR-pY1068-Peptide and STAT3-pY705-Peptide) were purchased from Cell
Signaling for peptide competition assay in IHC.

2.3 Construcs and shRNAs
pcDNA6.A-EGFR, expressing full-length human EGFR with a carboxyl-terminal
myc-6×His tag, was constructed and described previously(Hsu et al., 2009). EGFR
extracellular domain plus transmembrane region (EC, amino acids 1-644), EGFR
intracellular domain (IC, amino acids 645-1186), EGFR deletion of C-terminal (∆CD, amino
acids 1-955) were subcloned into pcDNA6.A/myc-His vector (Invitrogen). Kinase-dead
EGFRK721R (KD EGFR) was generated using the Quick-Change Site-Directed Mutagenesis
22

Kit according to the manufacturer’s instruction (Stratagene). Full-length human Ago2 was
amplified from the cDNA of HeLa cells and subcloned into a modified pCMV5 vector
containing an N-terminal FLAG tag. Functional domains of Ago2 (FDM1: 1-372 aa; FDM2:
1-517 aa; FDM3: 227-860 aa; FDM4: 373-860 aa; FDM5: 518-860 aa) were subcloned into
the same pCMV5 vector for mapping protein regions binding with EGFR. For in vitro pulldown and kinase assays, full-length Ago2, Ago2-FDM2 and Ago2-FDM4 were subcloned
into pGEX6P1-GST vector. For generating YFP-interaction system, full-length EGFR and
Ago2 were subcloned into pBABE-CMV-DEST-Neo (fused with YFPn, generated by Dr. S.
Zhou) and pBABE-CMV-DEST-Puro (fused with YFPc, generated by Dr. S. Zhou)
respectively. For generating HeLa TetOff-inducible stable clones, full-length WT EGFR,
KD EGFR and WT Ago2 (with fused C-terminal FLAG tag) were subcloned into PlvxTight-Puro vector (Clontech). For generating Ago2 stable clones, full-length Ago2 (with
fused C-terminal FLAG tag) were subcloned into pCDH-CMV-MCS-EF1-Puro (CD510B-1)
and pCDH-CMV-MCS-EF1-copGFP (CD511B-1, System Biosciences) vectors. All mutant
constructs of Ago2 (Y393F, Y393D, Y393E) were generated using the Quick-Change SiteDirected mutagenesis kit (Stratagene) and confirmed by DNA sequencing. For live-cell
imaging, WT-EGFR fused with C-terminal GFP was constructed and described
previously(Hsu et al., 2009). Full-length human Ago2 was subcloned into pTagBFP-C
vector (with N-terminal BFP tag). Human pre-microRNA Expression Constructs Lenti-miR192-WT (MI0000234) and Lenti-miR-21-WT (MI0000077) were purchased from System
Biosciences. Lenti-miR-192-3M and Lenti-miR-21-3M were generated using the QuickChange Site-Directed mutagenesis kit (Stratagene) and confirmed by DNA sequencing. The
pre-miRNA

sequence

of
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miR-192-3M

is:

GCCGAGACCGAGUGCACAGGGCUCUGACCUAUGAAUUGACAGCCAGUGGUGU
GGUCUCCCCUCUGGCUGCCAAUUCCAUAGGUCACAGGUAUGUUCGCCUCAAU
GCCAGC;

the

pre-miRNA

sequence

of

miR-21-3M

is:

UGUCGGGUAGCUUAUCAGACUGAUGUUGACUUAUUAAUCUCAUGGCAACACC
AGUCGAUGGGCUGUCUGACA (red color highlights the nucleotides that were mutated).
RNA interference was performed using lentiviral short hairpin RNAs (shRNAs) from
MISSIONTM TRC-Hs (human) shRNA Library according to the instructed protocol.
Lentiviral packaging system, pCMV-dR8.2 dvpr (#8455) and pCMV-VSVG (#8454),
pBabe-puro-WT-VHL (#19234) were bought from Addgene. The oligo sequences of
shRNAs are listed below and confirmed by DNA sequencing. ON-TARGETplus NonTargeting Pool (D-001810-10) and ON-TARGETplus DICER1 siRNA SMARTpool
(targeting CDS of Dicer) were purchased from Dharmacon, Thermo Scientific.
Scrambled Control (#1864, Addgene):
CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG;
EGFR shRNA-E1 (TRCN0000121067):
CCGGGCTGCTCTGAAATCTCCTTTACTCGAGTAAAGGAGATTTCAGAGCAGCTT
TTTG (targeting 3’ UTR of EGFR);
EGFR shRNA-E2 (TRCN0000121068):
CCGGGCCACAAAGCAGTGAATTTATCTCGAGATAAATTCACTGCTTTGTGGCTTT
TTG (targeting CDS of EGFR);

24

Grb2 shRNA-1 (TRCN0000029372):
CCGGGATCTACATCTGTCTCCAGAACTCGAGTTCTGGAGACAGATGTAGATCTT
TTT (targeting CDS of Grb2);
Grb2 shRNA-2 (TRCN0000029373):
CCGGCAGATATTCCTGCGGGACATACTCGAGTATGTCCCGCAGGAATATCTGTT
TTT (targeting CDS of Grb2);
HIF1α shRNA#1 (TRCN0000003810):
CCGGGTGATGAAAGAATTACCGAATCTCGAGATTCGGTAATTCTTTCATCACTTT
TT (targeting CDS of HIF1α);
HIF1α shRNA#2 (TRCN0000010819):
CCGGTGCTCTTTGTGGTTGGATCTACTCGAGTAGATCCAACCACAAAGAGCATT
TTT (targeting 3’ UTR of HIF1α);
EPAS1/HIF2α shRNA#1 (TRCN0000003806):
CCGGCAGTACCCAGACGGATTTCAACTCGAGTTGAAATCCGTCTGGGTACTGTT
TTT (targeting CDS of HIF2α);
EPAS1/HIF2α shRNA#2 (TRCN0000003805):
CCGGGCGCAAATGTACCCAATGATACTCGAGTATCATTGGGTACATTTGCGCTT
TTT (targeting CDS of HIF2α).

2.4 Mass Spectrometry
Mass spectrometric analysis was performed as previously described(Lee et al., 2008).
Briefly, endogenous EGFR was purified by immunoprecipitation with anti-EGFR antibody
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(Ab-13) and analyzed by SDS-PAGE. All the protein bands co-immunoprecipitated with
EGFR was excised and analyzed by nanoelectrospray mass spectrometry for protein ID
identification. To identify phosphorylation sites of Ago2, we purified FLAG-tagged Ago2
that co-expressed with EGFR in 293T cells and analyzed the results by SDS-PAGE and
Western-Blot. The protein band corresponding to Ago2 was excised and subjected to in-gel
digestion with trypsin. After being isolated from the gel, samples were analyzed by
nanoelectrospray mass spectrometry, using an Ultimate capillary LC system (LC Packings)
coupled to a QSTARXL quadrupole time-of-flight mass spectrometer (Applied
Biosystem/MDS Sciex). All the identified phospho-residues were further confirmed by
manual interpretation of the spectra.

2.5 RNA Deep Sequencing and Hierarchical Clustering Analysis
Customized Next-Generation RNA deep sequencing, including both small RNA
application and whole transcriptome analysis, was performed according to the standard
procedure instructed by Applied Biosystems. All the RNA sequencing data were deposited
to GEO with accession number GSE44804. Briefly, total RNA was extracted from HeLa
stable clones expressing scrambled control (S) or EGFR shRNA-E1 (E1) that were seeded at
same density and cultured under normoxia or hypoxia (1% Oxygen) for 24 hours. All RNA
samples passed quality test with RIN-values greater than 8 as measured by Agilent
Technologies Bioanalyzer, were subjected to RNA deep sequencing. For whole
transcriptome analysis, SOLiD fragment colorspace transcriptome reads (50nt) were
mapped to the human genome (hg19) and assigned to ensemble transcripts using Bioscope
1.3.1 (Life Technologies). The values of reads per kilobase per million reads (RPKM) were
determined by Bioscope 1.3.1 CountTags tool using default parameters. Primary alignments
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with a minimum mapping quality of 10 and minimum alignment score of 10 were counted.
For small RNA analysis, library inserts were size selected between 18 and 40nts and
analyzed using CLC Genomics Workbench 4.7.1. 35nt colorspace reads were trimmed of
adaptor sequence and mapped against human pre-miR sequences (miRBase version 16.0).
Values of reads per million mapped reads (RPM) were based on mapped reads with no more
than 2 mismatches total. A read was considered to come from a mature miRNA if it mapped
to pre-miRNA sequences with no more than three upstream or downstream bases, and
missing no more than two upstream or downstream bases from predicted mature or mature*
sequences as defined in miRBase version 16.0. All the other pre-miRNA mapped reads were
assigned as pre-miRNA signal. For Hierarchical Clustering Analysis, Data files from small
RNA or whole transcriptome analysis were first filtered based on the normalized expression
value RPM (cutoff genes with all mapped reads ≤100 counts) or RPKM (filtered with count
value ≥0.5 RPKM). Gene expression profiles were then transformed into Log2 data for
comparing expression differences. For miRNA maturation analysis, we transformed the
original expression data (Log2 transformed) into relative expression of pre- and mature
miRNA levels that affected by EGFR knockdown (as calculated by expression change-fold).
We define relative expression of pre- or mature miRNA＝Log2 (pre- or mature miRNA in
HeLa scrambled control)-Log2 (pre- or mature miRNA in HeLa EGFR shRNA-E1 stable
clone). For identifying the mRNAs that regulated by EGFR and likely targeted by topscoring mHESM, mRNAs modulated by EGFR knockdown (with Log2 fold-change affected
by EGFR ≥ 0.4 or ≤ -0.4) were sorted and over-lapped with the predicted mRNAs (based on
published data and TargetScan prediction with total context score ≤ -0.20) that targeted by
top-scoring mHESM. For all the other analysis, Log-transformed gene expression files were
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further normalized by mean centering to correct average gene expression from all the
samples as log2-ratio of 0. Centroid Linkage Clustering was performed and the interactive
graphical results from Cluster were further analyzed by TreeView for displaying heatmaps.

2.6 qRT-PCR assays and Northern-Blot analysis
qRT–PCR assays as described previously26 were performed to measure the expression
of mRNA, pri-, pre- and mature miRNAs with some adaptations. Briefly, cells were washed
twice with PBS and immediately lysed in QIAzol. For mRNA, pri- and mature miRNA
detection, half of the lysed sample was subjected to total RNA extraction using miRNeasy
Mini Kit (Qiagen). For pre-miRNA detection, the other half of the lysed sample was
subjected to small RNA fraction purification using the miRvana miRNA isolation kit
(Ambion). To measure the expression of mRNA or pri- or pre-miRNAs, cDNA was
synthesized from 1ug purified total RNA or 500ng purified small RNA (size-fractioned) by
SuperScript III First-Strand cDNA synthesis system using random hexamers (Invitrogen)
according to the manufacturer’s instructions. qPCR was performed using real-time PCR
machine (iQ5, BioRad). For detection of mature miRNAs, TaqMan MicroRNA assay kit
(Applied Biosystems) was used in accordance with the manufacturer’s protocol. qPCR was
performed using 7500 Fast Real-Time PCR System (Applied Biosystems). All the data
analysis was performed using the comparative Ct method. Results were first normalized to
internal control β-actin mRNA or U6 snRNA, which were almost not affected by hypoxia or
EGFR knockdown, and then the relative expression of pri-, pre- or mature miRNAs in
response to hypoxia was given by normalized expression level under hypoxia relative to the
corresponding normalized expression under normoxia. Each RNA sample (except for RIP
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experiment) was analyzed in duplicate and presented as an average of two independent RNA
preparations. The sequences of qPCR primers are given in the Supplementary Information.
Northern-Blot analysis was performed as described previously(Varallyay et al., 2008).
miRCURY LNA probes (targeting hsa-miR-21 or hsa-miR-192, Exiqon) and DNA
oligonucleotide

(5’-GGGGCCATGCTAATCTTCTCTGTATCGTTCCAATTTTAGT

ATATGTG-3’; Sigma) targeting U6 (internal control) were end-labeled with [γ-32P] ATP
and used as probes for Northern Blot analysis.

2.7 Immunoprecipitation and immunoblotting
Immunoprecipitation

and

immunoblotting

were

performed

as

previously

described(Lee et al., 2008). Briefly, cells were washed twice with cold PBS and scraped into
lysis buffer containing complete protease inhibitors (all the above steps were done inside of
the hypoxia chamber). After brief sonication, cell lysates were centrifuged at 14,000g for 20
min at 4°C to remove insoluble cell debris and then subjected to IP-WB.

2.8 Iodixanol continous density gradient
Optiprep iodixanol density media was obtained from Sigma-Aldrich. Continuous
density gradients were performed as described previously with some adaptations(Gibbings
et al., 2009). Briefly, HeLa cells seeded at the same density were either cultured under
normoxia or hypoxia (1% Oxygen) for 24 hr before collection. Cells were then washed twice
in PBS and re-suspended with PBS. 10% of the suspended cells were lysed by RIPA buffer
as the whole cell lysate input for later on protein analysis. The rest of the cells were resuspended in 500 µl 0.25 M sucrose, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM EGTA, 50 mM
Hepes-NaOH at pH 7.0 with complete protease inhibitors. Cells were lysed by 40 strokes of
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dounce homogenizer and 10 passages through a 26-gauge needle, and centrifuged at 1,000g
for 5 min twice to remove cellular debris and nuclei. Continuous 0–30% optiprep gradients
were prepared in 78 mM KCl, 4 mM MgCl2, 8.4 mM CaCl2, 10 mM EGTA and 50 mM
Hepes-NaOH at pH 7.0 using a gradient mixer (gradient station, Biocomp Instruments).
Postnuclear supernatant was added to the top of 13 ml gradients and centrifuged at 90,000g
for 20 h. Fractions (0.5 ml per fraction) were collected from the bottom of the gradient using
a fraction collector (BioFrac, BioRad) that measures conductivity to verify continuity of
gradients. For analysis, 30 µl whole cell lysate input (with total volume 500 µl) was loaded
along with 30 µl protein samples from each fraction (500 µl per fraction) in SDS-PAGE, and
subjected for WB and quantified by Odyssey Infrared Imaging System.

2.9 Generation of stable clones expressing GOI and shRNAs
YFP-interaction system (in HTC-1080 and HeLa cells) and RCC4 stable transfectants
expressing vector control or WT-VHL were generated by retroviral infection. All the other
stable clones expressing GOI or shRNAs were generated by Lentiviral infection. For
retroviral infection, packaging plasmids (gag/pol and VSV-G) were co-transfected with
pBABE-Neo-EGFR-YFPn or pBABE-Puro-Ago2-YFPc into 293T cells, and viral particles
were harvested at 48 hr post-transfection. HTC-1080 and HeLa cells were infected with one
or co-infected with both viruses for 24 hr in the presence of polybrene (10 µg/ml) and
subsequently selected by G418 (1,000 µg/ml) or puromycin (1 µg/ml) or G418 (500 µg/ml)
together with puromycin (0.5 µg/ml). For RCC4 stable transfectants, pBabe-puro-vector or
pBabe-puro-HA-WT-VHL together with pCL-Ampho (optional) was transfected into
phoenix cells, and viral particles were harvested at 48 hr post-transfection. The other steps
were the same as described above. HeLa TetOff-inducible stable clones were generated
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following the protocol instructed by Clontech. Briefly, 293T cells were seeded in DMEMF12 medium supplemented with 10% Tet-System Approved FBS (Clontech) for 24 hr
before transfection. Lentiviral packaging plasmids (generation II), pCMV-dR8.2-dvpr and
pCMV-VSVG, were co-transfected with lentiviral constructs expressing GOI (plvx-tightvector; WT or KD EGFR; WT or Y393F Ago2) into Tet-Free 293T cells. Viral particles
were harvested at 48 hr post-transfection and further infected into Tet-Free targeting cells
(HeLa TetOff Advanced Cell Line) for 24 hr in the presence of polybrene (10 µg/ml). At 48
hr post-infection, cells were selected by both G418 (500 µg/ml) and puromycin (1 µg/ml) in
DMEM-F12 medium supplemented with 10% FBS and doxycycline (500 ng/ml) for
generating stable clones without induction of GOI. For generating EGFR shRNA, Grb2
shRNA, HIF1α shRNA, HIF2α shRNA and other Ago2 stable clones (including knocking
down endogenous EGFR in HeLa CMV Ago2 stable clones and stable expression of miR192-WT, miR-192-3M, miR-21-WT and miR-21-3M in HeLa TetOff Ago2 stable clones),
similar lentiviral infection procedure (with no restriction of Tet-Free) was performed. Stable
clones were generated either by puromycin (2 µg/ml in HeLa; 1 µg/ml in MDA-MB-231)
selection or sorted twice by flow cytometry based on the expression of GFP.

2.10 miRNA-Reporter Assay
Oligonucleotides complementary to the sequences of mature miR-21, miR-31, miR192, miR-193a-5p or all of the later three seeding sequences were ligated into pMIRReporter (Ambion) and verified by DNA sequencing. HeLa TetOff Ago2 stable clones were
co-transfected with each miR-Reporter (firefly luciferase) together with internal control
(pRL-Renilla luciferase control reporter) and cultured under normoxia or hypoxia for 36-48
hr after doxycycline removal. The luciferase activity of miR-Reporter was determimed by
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the ratio of firefly to renilla luciferase as measured by the Dual-Luciferase Reporter Assay
System (Promega) and further normalized to the one of vector control cultured under
normoxia. The oligonucleotide sequences for each pMIR-Reporter are listed in the
Supplementary Information.

2.11 RNA-Binding Protein Immunoprecipitation (RIP-Assay)
RNA-Binding Protein Immunoprecipitation Kit (Magna RIP, Millipore) was used for
RIP-Assay, according to the manufacturer’s instruction. Briefly, HeLa TetOff Ago2 stable
clones were cultured under hypoxia for 24 hr after doxcycline removal and then treated with
MOCK (DMSO) or TKI (Iressa, 1 µM) for 8 hr before collection. Cells were lysed in RIP
Lysis Buffer with both protease inhibitor and RNase inhibitor, and 5% of the total cell
lysates were used for Western-Blot analysis as experimental control. FLAG antibody was
bound to the magnetic beads and added into each RIP reaction (RIP lysate in RIP
immunoprecipitation buffer with RNase inhibitor) for incubation O/N at 4 °C. Beads were
washed 6 times in cold RIP washing buffer and 10% of the beads were kept as RIP-input to
show the precipitated protein quantity of WT or Y393F Ago2. Proteins were digested in
Protease K buffer at 55 °C for 30 min, and total RNA was extracted using miRNeasy Mini
Kit (Qiagen). A 15-µl elution of RNA (with total volume 30 µl) was used for cDNA
systhesis and further analyzed by qPCR. Except for first-strand synthesis, the procedure for
RIP-Assay using HeLa TetOff Ago2 stable clones expressing ON-TARGET control siRNA
pool or ON-TARGET Dicer1 siRNA SMART pool is similar. After RNA purification from
anti-FLAG immunoprecipitates, 15-µl elution of RNA (with total volume 30 µl) was
synthesized into cDNA using SuperScript III with random hexamers (Invitrogen) for
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detection of miRNA precursors, while another 15-ul elution of RNA was reversely
transcribed into cDNA using TaqMan MicroRNA assay kit for detection of mature miRNAs.

2.12 In vitro Pull-Down Assay
Recombinant GST-Ago2 (full-length), GST-Ago2-FDM2, GST-Ago2-FDM4 and
GST were expressed in E. coli (BL-21) and purified by glutathione-sepharose beads. Similar
quantity of protein samples were incubated with in vitro transcription and translation lysates
of myc-tagged full-length EGFR (pCDNA6.a-WT-EGFR), produced by TNT coupled
reticulocyte lysate system (Promega), in binding buffer (25 mM Tris-HCl, pH 7.5, 125 mM
NaCl, 1 mM phenylmethylsulfonyl fluoride, 1 µg of leupeptin/ml, 1 µg of aprotinin/ml, and
1 µg of pepstatin/ml) for O/N at 4 °C. Beads were washed five times with Tris-buffered
saline and subjected to SDS-PAGE for autoradiography.

2.13 In vitro Kinase Assay
Recombinant GST-WT-Ago2 and GST-Y393F-Ago2 were incubated with or without
(negative controls) purified human EGFR (E2645, Sigma) in HTScan 1× tyrosine kinase
buffer (Cell Signaling) supplemented with 200 µM cold ATP and 2.5 mM DTT for 40 min
at 30 °C. The reaction of purified EGFR without substrate was carried out under the same
condition as another negative control. Kinase Assay was stopped by 8.5% phosphoric acid,
subjected to SDS-PAGE and analyzed by Western-Blot using 4G10 antibody.

2.14 Confocal Microscopy Analysis
Confocal Microscopy analysis was performed as described previously(Hsu et al.,
2011). Briefly, cells after treatment were washed three times with cold PBS, fixed in 4%
paraformaldehyde for 20 min at RT. For experiments under hypoxia, cells were washed with
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cold PBS and then added with 4% paraformaldehyde before moving out of the hypoxia
chamber. Cells were then permeabilized with 0.5% Triton X-100 for 10 min, and incubated
with 5% bovine serum albumin for 1 hr. After that, cells were incubated with primary
antibodies overnight at 4°C, and then washed with PBS, and further incubated with the
appropriate secondary antibody diluted at 1:300 and tagged with Alexa 488, Alexa 568 or
Alexa 647 (Molecular Probes) for 1 hr at room temperature. Nuclei were stained with 4,6diamidino-2-phenylindole (DAPI) before mounting. Confocal fluorescence images were
captured using a Zeiss LSM710 laser microscope. In all cases, optical sections through the
middle planes of the nuclei, as determined using nuclear counterstaining, were obtained. For
Live-Cell imaging, HeLa cells were co-transfected with EGFR-GFP and BFP-Ago2, and
then cultured under normoxia or hypoxia for 24 hr. 50 nM Lyso-Tracker (Red DND-99,
Invitrogen) was added into cells right before confocal analysis. Alternatively, HeLa cells coexpressing EGFR-GFP and BFP-Ago2 was further transduced with CellLight Rab7-RFP
(CellLight late endosome-RFP, Invitrogen) according to the manufactory’s instruction for 24
hr, and after that, cells were cultured under normoxia or hypoxia for 24 hr before confocal
analysis.

2.15 Duolink Assay (in situ Proximity Ligation Assay)
In situ Proximity Ligation Assay was performed according to manufacturer’s
instructions (OLINK BIOSCIENCE). Briefly, HeLa stable transfectants expressing
scrambled control or shRNAs (targeting Grb2 or HIF1α or HIF2α) were seed on 8-well
chamber slides and cultured under normoxia or hypoxia for 24 hr. Cells were then washed
(inside of the hypoxia chamber), fixed, permeablized and blocked before primary antibody
(against endogenous EGFR and Ago2) incubation at 4°C overnight. After washing,
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secondary antibodies conjugated with oligonucleotides (Minus and Plus) were added into
each reaction and incubated for 1 hr at 37°C. Cells were washed before adding ligation
solution and further incubated at 37°C for 30 min. Finally fluorescently labeled
oligonucleotides (FITC in our case) together with Polymerase were added into each reaction
for amplification of the original ligated nucleotide circles. The positive signal is visualized
as distinct fluorescence spot and each spot represents one cluster of protein-protein
interaction.

2.16 Cell Apoptosis Analysis
Evaluation of apoptosis by the annexin V-propidium iodide (PI) binding assay was
performed according to the standard protocol. APC-Annexin V and propidium iodide (PI)
(BD Biosciences) were prepared according to the manufacturer’s instructions. The extent of
apoptosis was quantified as percentage of annexin V-positive cells.

2.17 Cell Proliferation Assay
Cell proliferation was measured by BrdU Cell Proliferation Assay Kit (#6813, Cell
Signaling) according to the manufacturer’s instructions.

2.18 Soft Agar Assay
HeLa Ago2 stable clones (1×104cells) and MDA-MB-231 Ago2 stable clones
(5×103cells) were resuspended in DMEM containing 10% FBS with 0.5% agarose and
layered on top of 1.0% agarose in DMEM on 24-well plates. A 500-µl normal culture
medium containing 1 µg/ml puromycin was added to the top of each well and changed every
five days. Cultures were maintained for 15 days. Colonies that grew beyond 50 µm in
diameter were scored as positive. Each experiment was done in triplicate.
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2.19 Cell Migration Assay
Cell migration assays were performed in Biocoat transwell filter inserts (8um, 24-well
plates, BD Biosciences) as described previously with some adaptations. Briefly, Cells were
pre-treated with MOCK (DMSO) or TKI (Iressa, 1 µM) for 6 hr before trypsinization.
DMEM-F12 containing 10% FBS with MOCK or TKI was added to the bottom chamber.
Cell suspensions (2×104 HeLa Ago2 stable clones or 1×104 MDA-MB-231 Ago2 stable
clones) in serum-free DMEM-F12 with MOCK or TKI were added to the upper chamber.
After migration for 18 hr under normoxia or hypoxia, cells on the top surface of the
membrane were removed and the remaining cells, which migrated through the inserts, were
fixed and stained with crystal violet. The average number of migrated cells per field
(counted visually under a light microscope at original magnification ×200) was calculated
based on five randomly selected fields per membrane in triplicate.

2.20 Three-Dimensional Invasion Assay
The 3-D OrisTM cell invasion assay was performed according to the manufacturer’s
instructions (Platypus Technologies). Briefly, 100ul of the BME coating solution was added
into the wells (96-well-black plate, Platypus Technologies) and incubated in a humidified
cell culture chamber for 15-30 min for solidification. OrisTM cell seeding stoppers were
inserted perpendicular to each well bottom and fully engaged with the bottom of each well.
HeLa Ago2 stable clones (5×104 cells) were resuspended in 100ul DMEM-F12 medium
supplemented with 10% FBS and puromycin (1 µg/ml) with Mock (DMSO) or Iressa (1 µM).
Cell suspensions were added into each well through one of the side ports of the OrisTM cell
seeding stopper and allowed O/N for complete cell attachment. Stoppers were removed by
the OrisTM stopper tool. The top medium of each well was removed and any unattached cells
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were cleared by gently washing with PBS. 40ul OrisTM BME stock reagent mixed with
Mock or Iressa (1 µM) was added into each well to create a 3-D BME overlay. Then, the
plate was incubated in a humidified cell culture chamber for 30 min for polymerization of
the 3-D BME overlay. Finally, 100 µl of serum-free cell culture medium with Mock or
Iressa (1 µM) was added on the top of the 3-D BME overlay. We recorded full-images of the
well center (with no cells at T0) at different time points (T=0, T24=24 hr and T48=48 hr)
using a Zeiss LSM710 laser microscope. Invasion capacity was reported as the average
number of cells (5 different wells per experimental group) that invaded into the center of
wells in 48 hr.

2.21 Orthotopic xenograft breast cancer model
Orthotopic breast cancer mouse model was performed as previously described(Hsu et
al., 2011). Briefly, MDA-MB-231 cells (1×106 cells) were injected into the mammary fat
pads of nude mice (at Day 0). Two hours before sacrifice, mice were intraperitoneally
injected with Hypoxy-probe (pimonidazole hydrochloride, HPI, Inc.) at a dosage of 60
mg/kg body weight according to the manufacturer’s instructions. Five series of tumor
samples (2 mice per group) were collected every 4 days (started from Day 8 to Day 24) and
analyzed by IHC staining. All animal procedures were conducted under the guidelines
approved by the Institutional Animal Care and Use Committee (IACUC) at MD Anderson
Cancer Center (Protocol Number 06-87-06139).

2.22 Immunohistochemical Staining
Immunohistochemical staining was performed as previously described(Xia et al.,
2009). To validate the specificity of p-Y393-Ago2 antibody in IHC, we performed peptide
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competition assay by staining human breast tumor sample with p-Y393-Ago2 antibody
blocked with Mock or phospho-Y393-Ago2-peptide or non-phospho-Y393-Ago2-peptide, or
two randomly chosen phospho-tyrosine peptides, EGFR-pY1068-Peptide and STAT3pY705-Peptide (Cell Signaling), at the same concentration (1 µg/ml). The procedure for IHC
staining in orthotopic xenograft model was similar. The hypoxy-probe was stained using the
HypoxyprobeTM-1 Plus Kit (HPI, Inc.). Universal LSAB™+ Kit/HRP (Dako) was used for
detection of p-Y393-Ago2 in mouse xenograft tumor samples. Human breast tumor tissues
samples were obtained under the guidelines approved by the Institutional Review Board at
MD Anderson Cancer Center.

2.23 Primer Information for qPCR
Primers for qPCR

5’ to 3’

Notes

U 6-Forward:

CTCGCTTCGGCAGCACA

Internal Control

U 6-Reverse:

AACGCTTCACGAATTTGCGT

Internal Control

Pre-mir15b-Forward:

AGCACATCATGGTTTACATGC

*

Pre-mir15b-Reverse:

CTAGAGCAGCAAATAATGATTCG

*

Pre-mir16-1-Forward:

GCAGCACGTAAATATTGGCGT

*

Pre-mir16-1-Reverse:

CAGCAGCACAGTTAATACTGGAGA

*

Pre-mir16-2-Forward:

GCACGTAAATATTGGCGTAGT

*

Pre-mir16-2-Reverse:

AAGCAGCACAGTAATATTGGTG

*

Pre-mir24-1,2-Forward:

CTCCCGTGCCTACTGAGCT

*

Pre-mir24-1,2-Reverse:

CCCTGTTCCTGCTGAACTGAG

*

Pre-mir26a-1,2-Forward:

TTCAAGTAATCCAGGATAGGCTGT

*

38

Pre-mir26a-1,2-Reverse:

TGCAAGTAACCAAGAATAGGCC

*

Pre-mir26b-Forward:

TTCAAGTAATCCAGGATAGGCTGT

*

Pre-mir26b-Reverse:

CAAGTAATGGAGAACAGGCTG

*

Pre-mir27a,b-Forward:

GCAGGGCTTAGCTGCTTG

*

Pre-mir27a,b-Reverse:

GGCGGAACTTAGCCACTGT

*

Pre-mir29a,c-Forward:

ATGACTGATTTCTTTTGGTG

*

Pre-mir29a,c-Reverse:

ATAACCGATTTCAGATGGTG

*

Pre-mir34a-Forward:

TGGCAGTGTCTTAGCTGGTTG

*

Pre-mir34a-Reverse:

GGCAGTATACTTGCTGATTGCTT

*

Pre-mir100-Forward:

AACCCGTAGATCCGAACTTG

*

Pre-mir100-Reverse:

TACCTATAGATACAAGCTTGTGCG

*

Pre-mir103-1,2-Forward:

GCTTCTTTACAGTGCTGCCT

*

Pre-mir103-1,2-Reverse:

TTCATAGCCCTGTACAATGCT

*

Pre-mir107-Forward:

CAGCTTCTTTACAGTGTTGCCT

*

Pre-mir107-Reverse:

GATAGCCCTGTACAATGCTGC

*

Pre-mir125b-1-Forward:

GTCCCTGAGACCCTAACTTG

*

Pre-mir125b-1-Reverse:

AGCCTAACCCGTGGATTT

*

Pre-mir125b-2-Forward:

GTCCCTGAGACCCTAACTTG

*

Pre-mir125b-2-Reverse:

AAGAGCCTGACTTGTGATGT

*

Pre-mir138-1,2-Forward:

CAGCTGGTGTTGTGAATCAG

*

Pre-mir138-1,2-Reverse:

ACCCTGGTGTCGTGAAATAG

*

Pre-mir145-Forward:

GTCCAGTTTTCCCAGGAATC

★

Pre-mir145-Reverse:

AGAACAGTATTTCCAGGAAT

★
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Pre-mir191-Forward:

GCAACGGAATCCCAAAAG

*

Pre-mir191-Reverse:

GACGAAATCCAAGCGCA

*

Pre-mir192-Forward:

CTGACCTATGAATTGACAGCC

*

Pre-mir192-Reverse:

TGACCTATGGAATTGGCAG

*

Pre-miR193-Forward:

GTCTTTGCGGGCGAGAT

*

Pre-miR193-Reverse:

AACTGGGACTTTGTAGGCCA

*

Pri-mir21-Forward:

TTTTGTTTTGCTTGGGAGGA

Pri-mir21-Reverse:

AGCAGACAGTCAGGCAGGAT

Pri-mir31-Forward:

TGAGTGTGTTTTCCCTCCCT

*

Pri-mir31-Reverse:

GCCATGGCTGCTGTCAG

*

Pri-miR-192-Forward:

TGGTGGCGGGTAGTGGA

Pri-miR-192-Reverse:

TGGCATTGAGGCGAACAT

Pri-miR-193a-Forward:

ACCCCGAACTCCGAGGAT

Pri-miR-193a-Reverse:

TGGGACTTTGTAGGCCAGTT

EIF2C2-Q-Forward:

CACCATGTACTCGGGAGCC

EIF2C2-Q-Reverse:

CAAAGTCGGGTCTAGGTGGA

Dicer1-Q-Forward:

GAGCTGTCCTATCAGATCAGGG

Dicer1-Q-Reverse:

ACTTGTTGAGCAACCTGGTTT

ACTB-Q-Forward:

GCACAGAGCCTCGCCTT

Internal Control

ACTB-Q-Reverse:

GTTGTCGACGACGAGCG

Internal Control

Notes:
(1) For detection of mature miRNAs, TaqMan MicroRNA assay kits (Applied Biosystems)
were used in accordance with the manufacturer’s protocol.
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(2) For pre-miR-31 detection, we used Hs_mir-31_1_PR miScript Precursor Assay (Qiagen)
in accordance with the manufacturer’s protocol.
(3) The primer sequences marked with “*” were from Jiang et al(Jiang et al., 2005).
(4) The primer sequences marked with “★” were from Suzuki et al26.

2.24 Oligonucleotide sequences for pMIR-Reporter
Oligonucleotide

5’ to 3’

miR-21-binding-F:

CTAGTTCAACATCAGTCTGATAAGCTAA

miR-21-binding-R:

AGCTTTAGCTTATCAGACTGATGTTGAA

miR-31-binding-F:

CTAGTAGCTATGCCAGCATCTTGCCTA

miR-31-binding-R:

AGCTTAGGCAAGATGCTGGCATAGCTA

miR-192-binding-F:

CTAGTGGCTGTCAATTCATAGGTCAGA

miR-192-binding-R:

AGCTTCTGACCTATGAATTGACAGCCA

miR-193a-5p-binding-F:

CTAGTTCATCTCGCCCGCAAAGACCCAA

miR-193a-5p-binding-R:

AGCTTTGGGTCTTTGCGGGCGAGATGAA

miR-31-192-193a-binding-F:

CTAGTCATCTTGCCTCATAGGTCAGCAAAGACCCAA

miR-31-192-193a-binding-R:

AGCTTTGGGTCTTTGCTGACCTATGAGGCAAGATGA
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Hypoxia through Phosphorylation of Argonaute2
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3.1 EGFR interacts with Ago2 in response to hypoxia
3.1.1 Ago2 is a novel EGFR-interacting protein
Activated epidermal growth factor receptor (EGFR) encompassed in intracellular
vesicles is capable of activating intracellular signaling pathways before lysosomal
degradation (Gould and Lippincott-Schwartz, 2009). Importantly, proteins associating with
internalized EGFR likely differ from those transducing signaling at plasma membrane
(Mosesson et al., 2008), suggesting a higher degree of signaling complexity that is not well
characterized. By mass spectrometric analysis, we identified Ago2 as a novel EGFRinteracting protein (Fig. 3-1), and validated their association by co-immunoprecipitation
(Co-IP) and pull-down assays (Fig. 3-2). The Juxt/Kinase domain of EGFR is essential for
binding with Ago2 at the N-terminal region.
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Figure 3-1 Ago2 is a novel EGFR-interacting protein, in addition to those previously reported
(Huo et al., 2011).
Immunoprecipitation was performed in serum-starved EGF treated HeLa cells (with moderate
expression of EGFR) with IgG control or anti-EGFR antibody Ab-13. Unique peptides of
Argonarute2 were identified by mass spectrometric analysis in EGFR-immunoprecipitated protein
sample, as shown by silver staining of the representative purification of endogenous EGFR.
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Figure 3-2 EGFR Juxt/Kinase domain and the N-terminal region of Ago2 are required for
direct protein-protein association.
a, FLAG-tagged Ago2 was co-expressed with vector-control, full-length EGFR (with or without
Iressa treatment), Kinase-Dead EGFRK721R or different functional domains in 293T cells. Anti-FLAG
immunoprecipitates were blotted with myc antibody to show the interaction between EGFR and
Ago2. The efficacy of Iressa (tyrosine kinase inhibitor targeting EGFR) treatment was verified by the
reduced tyrosine phosphorylation of EGFR. * indicates the non-specific signal recognized by FLAG
antibody. b, Myc-tagged WT-EGFR was co-expressed with vector-control, FLAG-tagged full-length
Ago2 or different domains in 293T cells. Anti-FLAG immunoprecipitates were blotted with myc
antibody to show the interaction between EGFR and Ago2.
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c

Figure 3-2 EGFR Juxt/Kinase domain and the N-terminal region of Ago2 are required for
direct protein-protein association.
c, Pull-down assay was performed by incubating in vitro translated full-length EGFR with purified
GST-control, GST-Ago2-FDM2, GST-Ago2-FDM4, or GST-full-length-Ago2. Protein samples were
precipitated with Glutathione-sepharose beads and subjected to SDS-PAGE, which was visualized
by S-35 radioisotopic detection. The quantity of precipitated GST-fusing protein is shown by
Coomassie blue staining.
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3.1.2 Hypoxia enhances the interaction between Ago2 and EGFR
Human Ago2 was initially reported as a membrane-associated cytoplasmic protein
(Cikaluk et al., 1999) and is the catalytic center of RNA-induced silencing complex (RISC)
(Eulalio et al., 2008). Ago2 also associates Dicer and TRBP (HIV-1 transactivating response
RNA-binding protein) to form the RISC loading complex, which is involved in the second
step of miRNA processing from pre- to mature miRNAs (Chendrimada et al., 2005;
Diederichs and Haber, 2007). To investigate the physiological role of EGFR-Ago2
interaction, we screened different upstream EGFR-activating stimuli, including ligands and
stresses (Franovic et al., 2007; Lemmon and Schlessinger, 2010; Reynolds et al., 2003;
Wang et al., 2009), in HTC-1080 stable clone expressing split-half-YFP-fused EGFR and
Ago2 (Fig. 3-3), in which the YFP fluorescence can only be reconstituted upon proteinprotein association (Lee et al., 2010) (Fig. 3-4a). Of the four different types of stimuli,
hypoxic stress induced the strongest level of YFP fluorescence (Figs. 3-3, 3-5) with distinct
foci formed in cytoplasm (Fig. 3-4b), suggesting that internalized EGFR interacts with Ago2
in aggregates. Dynamic EGFR-Ago2 association was further validated in HeLa cells and
various cancer cell lines by Co-IP (Figs. 3-4c, 3-6) and co-localization assays (Figs. 3-7, 38), and was found to be RNase-resistant (Fig. 3-9), supporting that EGFR and Ago2 are
direct physical interacting partners in vivo.
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a

b

Figure 3-3 EGFR interacts with Ago2 in response to hypoxia and oxidative stress.
To be continued in next page.
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c

Figure 3-3 EGFR interacts with Ago2 in response to hypoxia and oxidative stress.
a, Western blot analysis of total cell lysates from HTC-1080 parental and HTC-1080 stable
transfectants expressing Ago2-YFPc, EGFR-YFPn or both EGFR-YFPn and Ago2-YFPc, as
indicated. b, YFP fluorescence (detected by Flow Cytometry in FITC channel) was induced upon coexpression of EGFR and Ago2, and was further enhanced when cells were cultured under hypoxia or
oxidative stress. SF: Serum-Free O/N; EGF: 20 ng/ml; TGF-α: 10 ng/ml; Cisplatin: 50 µM;
Etoposide: 50 µM; SA: Sodium Arsenite (500 µM); H2O2: 500 µM; Hypoxia: 1% O2. Dashed line
indicates the basal level of fluorescence detected in serum-starved HTC-1080 stable transfectant coexpressing EGFR and Ago2. All data were normalized to the one of HTC-1080 parental cells
(Relative YFP Fluorescence = YFP Fluorescence － Auto-Fluorescence detected in HTC-1080
parental cells) with default setting Auto-Fluorescence =0. Statistical analysis was carried out using
student’s t test. The group of treatment was compared to its corresponding experimental control
(ligands vs. SF; Cisplatin and Etoposide vs. MOCK; SA, H2O2 and hypoxia vs. NC). Data are shown
as mean ± s.d., n=3. *indicates P<0.05. c, Representative live-cell images showing Hypoxia induced
YFP fluorescence in HTC-1080 stable transfectant co-expressing split-half-YFP-tagged EGFR and
Ago2. Living cells were stained with Hoechst (marker for nuclear) to show the cytoplasmic
localization of the YFP foci as marked by red arrows.
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Figure 3-4 EGFR interacts with Ago2 in response to hypoxia.
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Figure 3-4. EGFR interacts with Ago2 in response to hypoxia.
a, Split-half-YFP-fused EGFR and Ago2 were stably expressed in HTC-1080 cells to screen
for upstream stimuli that might trigger EGFR-Ago2 interaction. E, EGFR; A, Ago2. b, Top,
representative live-cell image. N, nuclear; C, cytoplasmic. Bottom, FACS analysis of HTC1080 stable transfectants as indicated. c, IP-Western blot analysis of HeLa cells in response
to different stimuli. EGF, 20 ng/ml; SA, 500 µM; hypoxia, 1% O2. d, Confocal microscopy
analysis of live HeLa cells as indicated. Rab7, a marker for late endosomes/MVBs. NC,
normoxia; H24, hypoxia 24 hr. e, IP-Western blot analysis of HeLa stable transfectants
expressing HIF1/2α shRNAs.

Figure 3-5 EGFR interacts with Ago2 in response to hypoxia and oxidative stress.
Similar YFP-interaction system was generated in HeLa cell line. The YFP fluorescence (detected in
FITC channel) of HeLa stable transfectant (expressing both EGFR-YFPn and Ago2-YFPc) in
response to ligand stimulation (EGF, 20 ng/ml), SA treatment (500 µM) or hypoxia (1% O2) was
analyzed by flow cytometry. All the data were normalized to the basal level of fluorescence in SF
(serum-free O/N) group. Statistical analysis was carried out using student’s t test. Data are shown as
mean ± s.d., n=3. **indicates P<0.01.
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Figure 3-6 EGFR-Ago2 interaction was enhanced by hypoxia in multiple cell lines.
Western blot analysis of endogenous EGFR immunoprecipitated from MCF-10A (breast); MCF-12A
(breast); BT-549 (breast); MDA-MB-231 (breast); Hep3B (liver) and A-549 (lung) cells cultured
under normoxia or hypoxia, as indicated. HIF1α was used as a positive control for cell hypoxic
response. β-actin was used as protein loading control.
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Figure 3-7 EGFR colocalizes with Ago2 in a sub-population of SA-induced stress granules (as
marked by GW182, Dcp1A and Ago2)
a, HeLa cells were cultured in normal medium or treated with 500 µM sodium arsenite (SA, classical
stress granule inducer) for 30 min. Cells were fixed and stained against endogenous Ago2 (red),
GW182 (magenta), EGFR (green) and DAPI (blue). Stress granules are indicated by the SA-induced
colocalization of Ago2 and GW182(Parker and Sheth, 2007). Right: magnification of image insets.
b, Left, HeLa cells with same treatments as panel a were fixed and stained against endogenous Ago2
(magenta), Dcp1A (red), EGFR (green) and DAPI (blue). Stress granules are indicated by the SAinduced colocalization of Ago2 and Dcp1A (Parker and Sheth, 2007). Right, enlargement of the
insets.
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Figure 3-8 EGFR colocalizes with Ago2 in response to hypoxic stress.
HeLa cells were cultured under normoxia or hypoxia (1% O2) for 24 hr. Cells were then fixed and
stained against endogenous Ago2 (magenta), EGFR (green) and DAPI (blue). Right: magnification
of image insets.
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Figure 3-9 Hypoxia-enhanced EGFR-Ago2 interaction is resistant to RNase treatments.
Western blot analysis of total cell lysates and EGFR immunoprecipitates from HeLa cells that were
cultured under normoxia or hypoxia for 24 hr, as indicated. Cell lysates were treated with 2 µg
RNase A (cleaving single-stranded RNA, Sigma) with or without 500 units of ribonuclease inhibitor
RNase-Out (Life Technologies) or 100 unites of RNase If (single strand specific RNA endonuclease,
NEB) as indicated at 4 °C overnight before performing immunoprecipitation. N, normoxia; H,
hypoxia for 24 hr.
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3.1.3 EGFR interacts with Ago2 at MVBs in response to hypoxia
Hypoxia is known to upregulate EGFR (Franovic et al., 2007) and prolong its
activation through retention in endocytic trafficking (Wang et al., 2009). Indeed, hypoxia
enhanced EGFR expression in late endosomes/multivesicular bodies (MVBs; F2-F4, Fig. 310), where it co-localized with Ago2 (Figs. 3-4d, 3-11) and co-fractionated (Fig. 3-10) with
RISC components (Ago2, Dcp1A, and GW182) as well as the RISC loading complex (Dicer,
TRBP, and Ago2). Silencing Grb2, a key modulator of EGFR endocytosis (Jiang et al.,
2003), diminished EGFR-Ago2 interaction (Fig. 3-12), highlighting the importance of
internalization. Furthermore, inhibition or silencing of hypoxia-inducible transcriptional
factors (HIF1/2α) (Bertout et al., 2008) reduced EGFR-Ago2 association (Figs. 3-4e, 3-13a)
and colocalization (Figs. 3-13b, 3-14) under hypoxia while stabilization of HIF1/2α
triggered their interaction under normoxia (Fig. 3-15). Nonetheless, EGFR-Ago2 association
in RCC4 cells (endogenous VHL null with constitutively expressed HIF1/2α) was further
strengthened by hypoxia regardless of the exogenous expression of WT-VHL (Fig. 3-16).
These results indicate that stable expression of HIF1/2α is sufficient to trigger EGFR-Ago2
interaction that is further enhanced by hypoxia likely through a HIF1/2α-independent
mechanism.
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Figure 3-10 EGFR is co-fractionated with RISC loading complex and RISC complex at late
endosome/MVB (multivesicular body).
Left, Western blot analysis of endogenous EGFR, Ago2, and other known components of RISC
(Eulalio et al., 2008) and RISC loading complex (Diederichs and Haber, 2007), as indicated, in cell
fractions from early endosomes (F1-2, indicated by Actin, EEA1 and Hrs), late endosomes/MVB
(F2-4, indicated by Hrs, Alix, Actin and Lamp1), to lysosomes (F4-12, indicated by Lamp1). Ago2
was enriched in late endosomes/multivesicular bodies (MVBs), consistent with previous reports
(Gibbings et al., 2009; Lee et al., 2009). N, cultured under normoxia; H, cultured under hypoxia for
24 hr. Right, relative expression (each fraction signal was normalized according to its corresponding
WCL-input) of EGFR and Ago2 in each fraction as indicated.

57

Figure 3-11 EGFR colocalizes with Ago2 at late endosomes/MVBs or lysosomes in response to
hypoxia.
HeLa cells co-transfected with EGFR-GFP (green) and BFP-Ago2 (blue) were cultured under
normoxia or hypoxia (1% O2) for 24hr. Cells were stained with 50 nM Lyso-Tracker (red color,
accumulated in low internal PH compartments(Knodler and Steele-Mortimer, 2005)) right before
live-cell confocal imaging. Hypoxia enhanced colocalization of EGFR and Ago2 at late
endosomes/MVBs/lysosomes is indicated by the positive staining of Lyso-Tracker. Right:
magnification of image insets.
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Figure 3-12 Grb2-mediated internalization is critical for the interaction between EGFR and
Ago2.
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Figure 3-12. Grb2-mediated internalization is critical for the interaction between
EGFR and Ago2.
a, Western blot analysis of total cell lysates and EGFR immunoprecipitates from HeLa
stable transfectants expressing scrambled control or shRNAs targeting Grb2 that were
cultured under normoxia or hypoxia for 24 hr as indicated. S, scrambled control; G1, Grb2
shRNA1; G2, Grb2 shRNA2. HIF1α was used as positive control for cell hypoxic response.
β-actin was used as protein loading control. b, Upper panel, in situ proximity ligation assay
was performed in HeLa stable transfectants expressing scrambled control or shRNAs
targeting Grb2 that were cultured under normoxia or hypoxia for 24 hr as indicated. Each
GFP foci indicated one cluster of EGFR-Ago2 colocalization. Lower panel, HeLa stable
transfectants treated the same as upper panel were fixed and stained against endogenous
EGFR (green) and DAPI (blue). Hypoxia enhanced EGFR internalization as marked by the
arrows in image ii. Grb2 knockdown blocked EGFR endocytosis as expected.

a

Figure 3-13 The transcriptional activity of HIF1/2α
α is important for hypoxia-enhanced EGFRAgo2 interaction.
a, Western blot analysis of total cell lysates and EGFR immunoprecipitates from HeLa cells that
were cultured under normoxia or hypoxia with or without HIF1/2α inhibitors for 24 hr as indicated.
The efficacy of HIF1/2α inhibitors was reflected by the reduced expression of LOX, a well-known
target of HIF1/2α (Erler et al., 2006). HIF1/2α as used as positive control for cell hypoxic response.
β-actin was used as protein loading control.
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b

Figure 3-13. The transcriptional activity of HIF1/2α
α is important for hypoxia-enhanced EGFRAgo2 interaction.
b, HeLa cells co-transfected with EGFR-GFP (green) and BFP-Ago2 (blue) were cultured under
hypoxia (1% O2) with or without HIF1/2α inhibitors (FM19G11 inhibits the transcriptional activity
of HIF1/2α (Moreno-Manzano et al., 2010); CAY10585 blocks HIF1α accumulation and reduces its
transcriptional activity (Basu et al., 2011) for 24hr. Cells were stained with 50 nM Lyso-Tracker (red
color, accumulated in low internal PH compartments) right before live-cell confocal imaging. Right:
magnification of image insets.

61

a

b

Figure 3-14 Both HIF1α
α and HIF2α
α are important for EGFR-Ago2 interaction in response to
hypoxia.
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Figure 3-14. Both HIF1α
α and HIF2α
α are important for EGFR-Ago2 interaction in
response to hypoxia.
a, In situ proximity ligation assay was performed in HeLa stable transfectants expressing
scrambled control or shRNAs targeting HIF1α or HIF2α as indicated that were cultured
under normoxia or hypoxia for 24 hr. Each GFP foci indicated one cluster of EGFR-Ago2
colocalization/interaction. b, Quantitative result for panel a. Fifty cells in each experimental
group were counted for the number of GFP foci per cell. Statistical analysis was carried out
using student’s t test. HIF1/2α knockdown cells were treated as one group to compare with
the scrambled control. Data are shown as mean ± s.d., n=50. *indicates P<0.05.

Figure 3-15 Stabilization of HIF1/2α
α by CoCl2 treatment finally enhanced EGFR-Ago2
interaction under normoxia.
Western blot analysis of the total cell lysates and EGFR immunoprecipitates from HeLa cells that
were treated with CoCl2 (100 µM) or cultured under hypoxia for 24 hr as indicated. The expression
of HIF1/2α was stabilized right after CoCl2 treatment for 6 hr (consistent with previous report
(Slomiany and Rosenzweig, 2006), whereas the interaction between EGFR and Ago2 was not
induced until 24 hr later (similar to what we found in EGFR-Ago2 association in response to
hypoxia), suggesting that downstream events of HIF1/2α stabilization may also play a role in EGFRAgo2 interaction.
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Figure 3-16 EGFR-Ago2 interaction was induced by hypoxia through HIF1/2α
α dependent and
independent mechanisms.
Western blot analysis of the total cell lysates and EGFR immunoprecipitates from RCC4
(endogenous VHL null with constitutively expressed HIF1/2α) stable transfectants expressing vector
control or WT-VHL that were cultured under normoxia or hypoxia for 24 hr. Re-expression of WTVHL in RCC4 cells reduced the expression of HIF1/2α as previously reported (Ivan et al., 2001) and
decreased the association between EGFR and Ago2. However, EGFR-Ago2 interaction in RCC4
vector control and WT-VHL stable clones was further induced by hypoxia regardless of the
constitutively expressed HIF1/2α.
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3.2 EGFR modulates miRNA maturation in response to hypoxia
To assess the functional importance of EGFR-Ago2 interaction in miRNA regulation,
we profiled RNA expression in HeLa stable clones expressing scrambled control or EGFR
shRNA-E1 under normoxia or hypoxia by RNA deep sequencing (Figs. 3-17a, 3-18).
Hierarchical clustering analysis of relative expression of pre- and mature miRNAs
(Scrambled vs. EGFR shRNA-E1, Fig. 3-17b) identified one distinct cluster of miRNAs
under hypoxia (dashed box, Fig. 3-19a). In the presence of EGFR, the level of pre-miRNAs
increased with a concomitant decrease in the expression of mature miRNAs. However, the
maturation of this cluster of miRNAs was not significantly altered by EGFR under normoxia
(Fig. 3-19a), implying that their processing from pre- to mature miRNAs was negatively
regulated by EGFR specifically in response to hypoxia. We defined this sub-cluster of
miRNAs as mHESM (miRNAs regulated by Hypoxia-dependent EGFR-Suppressed
Maturation). We then pooled mHESM and narrowed down the candidates based on their
absolute mature miRNA expression affected by EGFR knockdown. A majority of the topscoring mHESM turned out to be tumor suppressor-like (Leung and Sharp, 2007, 2010; Lu
et al., 2005; Nicoloso et al., 2009; Ventura and Jacks, 2009) (Fig. 3-20). To determine the
functional relevance of mHESM, mRNAs regulated by EGFR were sorted and overlapped
with the predicted mRNA targets of top-scoring mHESM, revealing 439 mRNAs that are
regulated by EGFR and also targeted by top-scoring mHESM (Fig. 3-19b). In response to
hypoxia, EGFR reduced the production of mHESM but enhanced the expression of
corresponding mRNA targets (Fig. 3-19b), supporting the importance of EGFR-modulated
miRNA maturation. The inhibitory role of EGFR in miRNA maturation in response to
hypoxia was further validated in HeLa stable transfectants expressing scrambled control or
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shRNAs targeting EGFR (Fig. 3-21) by quantitative PCR (qPCR). Moreover, induction of
WT but not kinase-dead (KD) EGFR in HeLa TetOff-inducible stable clones (Fig. 3-22a)
inhibited the maturation of top-scoring mHESM in response to hypoxia (Figs. 3-22b,c),
suggesting that EGFR kinase activity is important for EGFR-suppressed miRNA maturation.

a

b

Figure 3-17 Experimental design for RNA deep sequencing analysis.
a, Total RNA extracted from HeLa stable clones expressing scrambled control or EGFR shRNA
(shRNA-E1) that cultured under normoxia or hypoxia for 24 hr was analyzed by RNA deep
sequencing for both small RNA application and whole transcriptome analysis. E, EGFR; A, Ago2.
Red circles indicate the interaction between EGFR and Ago2. b, Definition of R-Pre and R-Mature
for Hierarchical Clustering Analysis.
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Figure 3-18 Verification of EGFR knockdown efficacy in HeLa stable transfectants for RNA
deep sequencing.
Western blot analysis of total cell lysates from HeLa stable clones expressing scrambled control or
EGFR shRNA-E1 that were cultured under normoxia or hypoxia for 24 hr. HIF1α was used as a
positive control for cell hypoxic response. β-actin was used as protein loading control. S, scrambled
control; E1, EGFR shRNA-E1.
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Figure 3-19 EGFR modulates miRNA maturation in response to hypoxia.
a, Top, hypothesized role of EGFR in miRNA maturation; Bottom, Hierarchical Clustering Analysis
of R-Pre and R-Mature
Mature identified one distinct cluster of miRNAs whose maturation was suppressed
by EGFR under hypoxia. We define this sub
sub-cluster as mHESM. b, Top, Venn diagram highlighting
the mRNAs that are regulated by EGFR and likely to be targeted by top
top-scoring
scoring mHESM. Bottom,
EGFR-mediated
mediated suppression of top
top-scoring mHESM concurrent with the up-regulation
regulation of targeting
mRNAs in response to hypoxia. A.E., aaverage expression.
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Figure 3-20 Hierarchical Clustering Analysis of top-scoring mHESM.
mHESMs were sorted based on their absolute mature miRNA expression affected by EGFR
knockdown. 20 top-scoring mHESM were selected (note: miR-193a includes miR-193a-5p and miR193a-3p) and tumor-suppressor-like miRNAs were marked with an asterisk (*). Expression of pre- or
mature miRNAs was log2 transformed and further normalized by mean centering to correct average
gene expression from all the samples as log2-ratio of 0. Centroid Linkage Clustering was performed
and the interactive graphical result from Cluster was analyzed by TreeView to display the heatmap.
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b

a

Figure 3-21 EGFR suppresses the maturation of mHESM in response to hypoxia.
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Figure 3-21 EGFR suppresses the maturation of mHESM in response to hypoxia.
a, Western blot analysis of HeLa stable clones expressing scrambled control or EGFR
shRNAs (E1, E2) that cultured under normoxia or hypoxia for 24 hr, as indicated. S,
scrambled control; E1, EGFR shRNA-E1; E2, EGFR shRNA-E2. HIF1α and HIF2α were
used as positive control for cell hypoxic response. β-actin was used as protein loading
control. b, Normalized relative expression (Log2) of pre- and mature miRNAs in HeLa
stable clones (verified in panel a) in response to hypoxia. Statistical analysis was carried out
using Student's t test. EGFR knockdown cells (E1 and E2) were considered as one group to
compare with the scrambled control. Data are shown as mean ± s.d., n=4, N-S indicates
P>0.05, * indicates P<0.05, **indicates P<0.01.
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Figure 3-22 EGFR kinase activity is essential for EGFR-suppressed miRNA maturation.
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Figure 3-22. EGFR kinase activity is essential for EGFR-suppressed miRNA
maturation.
a, HeLa TetOff-inducible stable clones expressing vector control, wild-type (WT) or kinasedead (KD) EGFR were generated and validated by Western blot. b, Western blot analysis of
HeLa TetOff-inducible EGFR stable clones that cultured under normoxia or hypoxia for 24
hr after doxycycline removal O/N. HIF1α was used as positive control for cell hypoxic
response. β-actin was used as protein loading control. c, Normalized relative expression
(Log2) of pre- and mature miRNAs in HeLa TetOff-inducible EGFR stable clones (verified
in panel b) in response to hypoxia. Statistical analysis was carried out using ANOVA or
student’s t test (comparing WT and KD EGFR). Data are shown as mean ± s.d., n=4.
**indicates P<0.01.
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3.3 EGFR phosphorylates Ago2 at Y393 to suppress the maturation of long-loop
mHESM in response to hypoxia
3.3.1 Ago2 is tyrosine phosphorylated by EGFR at Y393 in response to hypoxia
To investigate whether Ago2 is a phosphorylation substrate of EGFR, we purified
FLAG-tagged Ago2 co-expressed with EGFR and identified one tyrosine phosphorylation
site (Fig. 3-23) at a highly conserved residue Y393 (Fig. 3-24) in Ago2. Results from in
vitro kinase assay (Fig. 3-25a) further demonstrated Ago2-Y393 as a direct phosphorylation
site targeted by EGFR. Mutational analysis suggested that phospho-Y393-Ago2 exists in
vivo (Figs. 3-26, 3-27), which was then validated in HeLa TetOff-inducible Ago2 stable
clones (Figs. 3-25b, 3-28a) using the polyclonal antibody (p-Y393-Ago2) we generated (Fig.
3-29). Interestingly, hypoxia enhanced Ago2-Y393 phosphorylation (Fig. 3-25b) which in
turn reduced Ago2-Dicer/TRBP association (Figs. 3-25b, 3-26, 3-27), suggesting that EGFR
is a novel upstream regulator of RISC loading complex.
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Figure 3-23 Ago2 is tyrosine phosphorylated at residue 393 as identified by mass
spectrometric analysis.
Top left, Western blot verification showing the tyrosine phosphorylation of purified Ago2 that
co-expressed with EGFR in 293T cells. Tyrosine phosphorylation was detected by 4G10
antibody. Bottom, mass spectrometric analysis of Ago2 identified Tyr393 as the single
tyrosine residue that been phosphorylated in vivo. This phospho-tyrosine residue has
previously been reported (Rudel et al., 2011), but neither the enzyme required for this
phosphorylation nor the biological outcomes of Ago2-Y393 phosphorylation has been studied
so far.
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Figure 3-24 Tyr393 of hAgo2 is highly conserved among vertebrates and coexists in hAgo1,
hAgo4 but not hAgo3.
a, Sequence alignment of the AGO family around Y393 of hAgo2. Highlighted with blue are wellconserved amino acids (intensity indicates degree of conservation). Hs, Homo sapiens; At,
Arabidopsis thaliana; Dm, Drosophila melanogaster; Sp, Saccharomyces pombe; Ce,
Caenorhabditis elegans; Kp, Kluyveromyces polysporus; Nc, Neurospora crassa. b, The adjacent
amino acid sequence of hAgo2-Y393 (DPYVREFG) is identical among vertebrates. Hs, Homo
sapiens; Pt, Pan troglodytes; Bt, Bos taurus; Mm, Mus musculus; Rn, Rattus norvegicus; Dr, Danio
rerio.
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Figure 3-25 EGFR phosphorylates Ago2 at Y393 to suppress the maturation of long-loop
long
mHESM in response to hypoxia.
a, in vitro kinase assay detected by 4G10 antibody. b, Relative position of Y393 in the structure of
hAgo2 with bound guide RNA (Schirle and MacRae, 2012). c, IP-Western
Western blot analysis of HeLa
TetOff-inducible
inducible Ago2 stable clones
clones. d, Normalized expression of miRNA and corresponding
luciferase activity of miR-reporters
reporters, n=4. e, RIP enrichment of pre- and mature miRNAs,
miRNAs n=3. f and
g, Northern blot analysis as indicated
indicated. Dashed lines indicate different exposure time. Whole panel
data are shown in Figs. 3-35, 33-36. Data represent mean ± s.d.; * indicates P<0.05,, t test.
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Figure 3-26 Tyr393 of Ago2 is the major phosphorylation site targeted by EGFR in vivo and
the phosphorylation of this residue reduces Ago2 binding to Dicer.
IP-Western analysis of WT and Y393F Ago2 in 293T cells, as indicated. Expression of Y393F
mutant Ago2 or treatment with tyrosine kinase inhibitor (TKI) of EGFR abolished EGFR-mediated
tyrosine phosphorylation of Ago2 (Lanes 4, 5, 6, 7 vs. Lane 3), supporting this residue as a target of
EGFR. Interestingly, phosphorylation of Ago2 at Y393 reduced its interaction with Dicer, which can
be restored by either TKI treatment (Iressa or AG1478) or by expressing the Y393F mutant Ago2
(Lane 3 vs. the other lanes). The quantitation of Dicer that interacts with Ago2 is shown below.
Iressa (1 µM), tyrosine kinase inhibitor (also known as gefitinib) used in clinic for targeting EGFR;
AG1478 (50 nM), specific EGFR inhibitor (Levitzki and Gazit, 1995) (IC50 for selective inhibition of
EGFR = 3 nM in vitro vs. IC50 for targeting HER2-neu and PDGFR >100 µM).
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Figure 3-27 Ago2-Y393 phosphorylation reduces Ago2-Dicer/TRBP interaction, which
however cannot be imitated by Y393D or Y393E mutant Ago2.
Left, Ago2 Y393 was mutated to phospho- and non-phospho-mimics. Right, IP-Western analysis of
WT, Y393F, Y393D and Y393E Ago2 in 293T cells, as indicated. WT Ago2 was tyrosine
phosphorylated by WT but not KD EGFR (Lane 5 vs. Lane 9). Mutating Tyr393 into phenylalanine
(F) or aspartic acid (Y393D) or glutamic acid (Y393E) abolished EGFR mediated tyrosine
phosphorylation of Ago2 (Lanes 6, 7, 8 vs. Lane 5). Ago2-Y393 phosphorylation reduced its binding
with Dicer and TRBP (Lane 5 vs. Lanes 1, 2, 6, 9, 10). Y393D and Y393E mutants showed similar
property as Y393F mutant, suggesting that both aspartic acid and glutamic acid cannot fully imitate
phosphorylated Y393 in Ago2. The phenomenon that phospho-tyrosine cannot be mimicked by
aspartic acid and glutamic acid was also reported previously (Anthis et al., 2009).
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Figure 3-28 Most mHESM regulated by Ago2-Y393 phosphorylation in response to hypoxia
contain long-loop structure in their precursors.
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Figure 3-28. Most mHESM regulated by Ago2-Y393 phosphorylation in response to
hypoxia contain long-loop structure in their precursors.
a, HeLa TetOff-inducible stable clones expressing vector control, WT or Y393F Ago2 were
generated and verified by Western blot, as indicated. * indicates the non-specific signal
recognized by FLAG antibody. b, Normalized relative expression (Log2) of mature
miRNAs in HeLa TetOff-inducible Ago2 stable clones (as verified in Fig. 3-25b) in
response to hypoxia. The structures of corresponding miRNA precursors were shown in the
diagram. Statistical analysis was carried out using student’s t test (comparing WT Ago2 or
vector control to Y393F Ago2). Data are shown as mean ± s.d., n=4, *indicates P<0.05.

a

Figure 3-29 Characterization of mouse polyclonal antibody against phospho-Y393-Ago2
(homemade).
a, Top, anti-FLAG immunoprecipitates (Sample-NO.1, 2, 3, 7) were blotted with homemade
antibody against p-Y393-Ago2. Bottom, Western blot analysis of corresponding anti-FLAG
immunoprecipitates and total cell lysates from 293T cells.
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b

Figure 3-29 Characterization of mouse polyclonal antibody against phospho-Y393-Ago2
(homemade).
b, Peptide competition assay for p-Y393-Ago2 antibody by immunohistochemical staining. Human
breast tumor sample showing high expression of EGFR (data not shown) also showed positively
staining of p-Y393-Ago2 using the homemade antibody. Importantly, the recognition capacity of this
antibody can be completely blocked with phospho-Y393-Ago2-peptide but not the control nonphospho-Ago2-peptide or the other randomly chosen phospho-tyrosine peptides, demonstrating its
fidelity in IHC staining for detecting Ago2-Y393 phosphorylation in vivo.
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3.3.2 Structural analysis of human Ago2
To gain more insight into phospho-Y393-Ago2, we analyzed the crystal structure of
human Ago2 (Schirle and MacRae, 2012) (hAgo2) and found that the side chain of Y393
protrudes from an exterior orientation towards a cavity between the N domain, an interaction
surface for EGFR, and the linker L2 (Fig. 3-25c). Y393 is exposed to solvent and some
distance from both the guide RNA-binding channel and the PIWI box, a Dicer-binding
region of hAgo2 (Tahbaz et al., 2004). Given that Dicer is a large protein, it is conceivable
that Dicer could still interact with both the Dicer-specific PIWI box and Y393 due to their
location on the same surface of hAgo2 (Fig. 3-25c). If so, phosphorylation of Y393 could
inhibit this interaction as previously observed (Figs. 3-25b, 3-26, and 3-27).

3.3.3 EGFR-mediated phosphorylation of Ago2 at Y393 suppresses miRNA
maturation in response to hypoxia
The recruitment of Ago2 to Dicer is critical for loading miRNA precursors onto RISC
loading complex (Maniataki and Mourelatos, 2005) and facilitating miRNA maturation
(Chendrimada et al., 2005; Maniataki and Mourelatos, 2005) from pre- to mature miRNAs.
We therefore investigated whether Ago2-Y393 phosphorylation plays a role in EGFRsuppressed miRNA maturation in response to hypoxia. Compared with Ago2-Y393F mutant,
induction of Ago2-WT significantly reduced the expression of most mHESM but not those
that do not belong to the mHESM cluster (defined as non-mHESM) in response to hypoxia
(Fig. 3-28b). Structural analysis of miRNA precursors determined that a majority of
mHESM regulated by p-Y393-Ago2 contained a long-loop structure, which is not present in
non-mHESM (Fig. 3-28b). Interestingly, mHESM that were not significantly affected by
Ago2-Y393 phosphorylation also had short-loop structures in their precursors similar to
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what we found in non-mHESM (Fig. 3-28b), suggesting the importance of long-loop
structure in regulation specificity. Similar expression patterns of mature miRNAs were also
observed in other paired stable clones (Figs. 3-30, 3-31). Silencing endogenous EGFR
significantly diminished the expression difference of long-loop mHESM present in miR-31,
miR-192, and miR-193a-5p between Ago2-WT and Ago2-Y393F mutant cells (Fig. 3-32).
The levels of their primary transcripts were reduced by EGFR knockdown under hypoxia
but similar between WT and Y393F Ago2 cells (Fig. 3-32b). This evidence supports
phospho-Y393-Ago2-suppressed miRNA maturation as a downstream event of EGFR under
hypoxia. Moreover, decreased expression of long-loop mHESM as shown in miR-31, miR192 and miR-193a-5p under hypoxia resulted in the de-repression of miRNA targets (Fig. 325d) as measured by miR-Reporter luciferase activity. In contrast, the expression of miR-21
(non-mHESM) and repression of its target were not significantly affected by Ago2-Y393
phosphorylation (Fig. 3-25d). These results underline the functional importance of p-Y393Ago2-mediated suppression of long-loop mHESM under hypoxia.
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Figure 3-30 Ago2-Y393 phosphorylation reduces the production of most mHESM in HeLa
non-inducible stable transfectants in response to hypoxia.
a, Western blot verification for non-inducible Ago2 stable clones generated in HeLa cell line, as
indicated. b, qPCR verification for the mRNA expression of WT and Y393F Ago2 in HeLa noninducible stable transfectants. β-actin mRNA was used as internal control. c, Normalized relative
expression (Log2) of mature mHESM in HeLa non-inducible Ago2 stable clones, as verified in
panels a and b, in response to hypoxia. Statistical analysis was carried out using student’s t test
(comparing WT- and Mut-Ago2). Data are shown as mean ± s.d., n=4, **indicates P<0.01.

85

c
a

b

Figure 3-31 Ago2-Y393 phosphorylation suppresses the production of most mHESM in MDAMB-231 stable transfectants in response to hypoxia.
a, Western blot verification for Ago2 stable clones generated in MDA-MB-231 cell line, as
indicated. b, qPCR verification for the mRNA expression of WT and Y393F Ago2 in MDA-MB-231
stable transfectants. β-actin mRNA was used as internal control. c, Normalized relative expression
(Log2) of mature mHESM in MDA-MB-231 Ago2 stable clones, as verified in panels a and b, in
response to hypoxia. Note: miR-31 was not expressed in MDA-MB-231 cell line. Statistical analysis
was carried out using student’s t test (comparing WT and Y393F Ago2). Data are shown as mean ±
s.d., n=4, *indicates P<0.05, **indicates P<0.01.
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Figure 3-32 EGFR is the tyrosine kinase that suppresses the processing of long-loop mHESM
through phosphorylation of Ago2 at Y393 in response to hypoxia.
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Figure 3-32. EGFR is the tyrosine kinase that suppresses the processing of long-loop
mHESM through phosphorylation of Ago2 at Y393 in response to hypoxia.
a, Western blot analysis of HeLa CMV Ago2 stable clones expressing scrambled control or
EGFR shRNA-E1 that cultured under normoxia or hypoxia for 24 hr. HIF1α and HIF2α
were used as positive control for cell hypoxic response. β-actin was used as protein loading
control. b, Top, normalized expression of pri-miRNAs in HeLa CMV Ago2 stable clones
expressing scrambled control or EGFR shRNA-E1, as verified in panel a, in response to
hypoxia. Bottom, corresponding normalized expression of mature miR-31, miR-192, miR193a-5p (long-loop mHESM) and miR-21 (non-mHESM). Silencing EGFR suppressed the
expression of pri-miR-31, pri-miR-192 and pri-miR-193a (long-loop mHESM
representatives) to a similar level among those stable transfectants under hypoxia; however,
it enhanced the level of corresponding mature miRNAs in vector control and WT but not
Y393F Ago2 cells. The expression of pri- and mature miR-21 (non-mHESM) was decreased
by EGFR knockdown, but was similar between WT and Y393F Ago2 stable clones. These
results indicate that increased expression of mature long-loop mHESM in vector control and
WT Ago2 cells after EGFR knockdown was not caused by transcriptional upregulation but
instead de-repression of miRNA maturation. S, scrambled control; E1, EGFR shRNA-E1.
Statistical analysis was carried out using Student's t test and the significance shown in the
diagram was based on the difference between vector control or WT and Y393F Ago2, or
between scrambled control and EGFR knockdown groups, as indicated. Data are shown as
mean ± s.d., n=4, * indicates P<0.05.
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3.3.4 Y393-phosphorylation of Ago2 attenuates its interaction with Dicer resulting
in suppressed miRNA maturation and reduced RISC activity
The long-loop structure in miRNA precursors is a known characteristic of Dicer’s
preference (Tsutsumi et al., 2011). Reduction in Dicer-Ago2 interaction resulted in less
loading of the precursors of miR-31, miR-192 and miR-193a-5p (long-loop mHESM), but
not miR-21 (short-loop non-mHESM), onto p-Y393-Ago2 under hypoxia (Fig. 3-33). To
examine the functional relevance of decreased Dicer-pAgo2 association, we knocked down
Dicer in HeLa TetOff-inducible Ago2 stable clones (Figs. 3-25e, 3-34a,b) and found the
differences between WT and Y393F Ago2 in miRNA precursor loading (Fig. 3-25e) and
mature miRNA expression (Fig. 3-34c) were significantly diminished. These results suggest
that the maturation of long-loop mHESM is suppressed by Ago2-Y393 phosphorylation
through Dicer. Moreover, Y393F Ago2 was capable of loading more mature mHESM (Fig.
3-25e), which is consistent with its enhanced RISC activity as indicated by luciferase
reporter assay (Fig. 3-25d). However, the mature miRNA loading difference between WT
and Y393F Ago2 was Dicer-dependent (Fig. 3-25e), and similar to what we observed in
mature miRNA expression (Fig. 3-34c). These data suggest that Ago2-Y393
phosphorylation decreases Dicer-Ago2 interaction along with reduced miRNA precursor
loading, which consequently suppresses the maturation of long-loop mHESM and decreases
the loading of corresponding mature miRNAs onto RISC under hypoxia.
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Figure 3-33 The precursors of long-loop mHESM as shown in pre-miR-31, pre-miR-192 and
pre-miR-193 but not pre-miR-21 (non-mHESM) were less loaded onto p-Y393-Ago2 under
hypoxia.
Top, qRT-PCR showing the loading difference between WT and Y393F mutant Ago2 in long-loop
mHESM precursors was significantly diminished by TKi (Iressa) treatment under hypoxia. RNA was
extracted from anti-FLAG immunoprecipitates in HeLa TetOff-inducible Ago2 stable clones that
cultured under hypoxia treated with Mock (DMSO) or Iressa (1 µM) for 24 hr as indicated. Data
were normalized to each corresponding negative control (anti-FLAG immunoprecipitate from HeLa
TetOff Plvx-Tight (vector control) stable transfectant cultured under hypoxia). Statistical analysis
was carried out using Student's t test and data are shown as mean ± s.d., n=3, * indicates P<0.05.
Bottom, IP-western control for RIP (RNA-binding protein immunoprecipitation) assay. p-Y1086EGFR was used as an indicator for the inhibitory efficacy of Iressa treatment. HIF1α was used as a
positive control for cell hypoxic response. β-actin was used as protein loading control.
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Figure 3-34 The maturation of long-loop mHESM was suppressed by Ago2-Y393
phosphorylation through Dicer.
a, Experimental flow chat. b, qPCR verification for the mRNA expression of Dicer and Ago2 in
HeLa TetOff-inducible Ago2 stable clones expressing control siRNA pool or Dicer siRNA pool
(Dharmacon, On-Target Plus siRNA) that were cultured under hypoxia for 24h, as indicated in flow
chat a. β-actin mRNA was used as internal control. c, Normalized expression of mature miR-31,
miR-192, miR-193a-5p (long-loop mHESM) and miR-21 (non-mHESM) as well as their precursors
and primary transcripts in HeLa TetOff-inducible Ago2 stable clones expressing control siRNA pool
or Dicer siRNA pool that were cultured under hypoxia for 24h, as indicated in flow chat a. Statistical
analysis was carried out using student’s t test (comparing vector control or WT to Y393F Ago2).
Data are shown as mean ± s.d., n=3, *indicates P<0.05.
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3.3.5 A long-loop structure in pre-miRNA confers regulation specificity
To demonstrate that the long-loop structure of pre-miRNAs indeed serves as one of
the determinants that distinguish mHESM regulated by p-Y393-Ago2 from the others, we
mutated pre-miR-192-WT (long-loop) into pre-miR-192-3M (short-loop) and stably
expressed them in HeLa TetOff-inducible Ago2 stable clones (top, Fig. 3-25f). Compared
with Ago2-Y393F mutant, induction of Ago2-WT attenuated the maturation of pre-miR192-WT but not pre-miR-192-3M, which virtually lost its processing efficacy without the
long-loop structure (Figs. 3-25f, 3-35). Conversely, Ago2-WT was able to suppress premiR-21-3M with a regenerated long-loop structure (Figs. 3-25g, 3-36) that is not present in
miR-21-WT (Fig. 3-25g, 3-37). These results support a long-loop-dependent mechanism by
which p-Y393-Ago2 confers regulation specificity on miRNA maturation.
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Figure 3-35 The long-loop structure in pre-miR-192 (long-loop mHESM) is required for pY393-Ago2-suppressed maturation under hypoxia.
a, Pre-miR-192-WT (long-loop) and pre-miR-192-3M (3 nucleotides were mutated, short-loop) were
stably expressed in HeLa TetOff-inducible Ago2 stable clones. Total RNA was extracted from the
stable transfectants as indicated and subjected to Northern Blot analysis. The detected mature miR192 signal was too weak compared with the precursors; therefore, data was shown in different
exposure time. b, Corresponding qPCR analysis. Control, stable expression of vector control; miR192-WT, stable expression of pre-miR-192-WT; miR-192-3M, stable expression of pre-miR-192-3M
in HeLa TetOff-inducible Ago2 stable clones. All the data were first normalized based on U6
internal control and then to the control group (HeLa TetOff WT Ago2, expressing vector control
with doxycycline treatment). Statistical analysis was carried out using Student's t test and data are
shown as mean ± s.d., n=3, * indicates P<0.05.
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Figure 3-36 Regeneration of a long-loop structure in pre-miR-21-3M renders it to be
suppressed by Ago2-Y393 phosphorylation under hypoxia.
a, Pre-miR-21-WT (short-loop) and pre-miR-21-3M (3 nucleotides were mutated, long-loop) were
stably expressed in HeLa TeOff-inducible Ago2 stable clones. Total RNA was extracted from the
stable transfectants as indicated and subjected to Northern Blot analysis. EB staining shows the
integrity of RNA samples and U6 was used as RNA loading control. b, Corresponding qPCR
analysis. Control, stable expression of vector control; miR-21-WT, stable expression of pre-miR-21WT; miR-21-3M, stable expression of pre-miR-21-3M in HeLa TetOff-inducible Ago2 stable clones.
All the data were first normalized based on U6 internal control and then to the control group (HeLa
TetOff WT Ago2, expressing vector control with doxycycline treatment). Statistical analysis was
carried out using Student's t test and data are shown as mean ± s.d., n=3, * indicates P<0.05.
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Figure 3-37 The maturation of endogenous miR-21 was not significantly affected by Ago2Y393 phosphorylation.
Total RNA was extracted from HeLa TetOff-inducible Ago2 stable clones cultured under normoxia
or hypoxia for 24 hr and subjected to Northern Blot analysis. V, vector control (Plvx-Tight); WT,
WT Ago2; Y393F, Y393F Ago2. EB staining shows the integrity of RNA samples and U6 was used
as RNA loading control.
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3.4 Functional assessments of Ago2-Y393-phosphorylation under hypoxia
3.4.1 Ago2-Y393-phosphorylation promotes cell survival and enhances cell
invasiveness in response to hypoxia
Hypoxic tumor microenvironment promotes metastatic phenotype by facilitating
tumor cell survival through evasion of apoptosis (Bertout et al., 2008). Given that most
mHESM suppressed by p-Y393-Ago2 are tumor-suppressor-like (Figs. 3-20, 3-28b), we
further investigated the pathophysiological role of Ago2 phosphorylation in response to
hypoxia. Compared with vector control and Ago2-WT, a higher proportion of cells
expressing Ago2-Y393F mutant underwent apoptosis following hypoxia exposure for 3 days
(Fig. 3-38), indicating that they were more susceptible to hypoxic stress. Knockdown of
endogenous EGFR reduced cell survival and diminished the differences in apoptosis
between Ago2-WT and Ago2-Y393F stable transfectants (Fig. 3-39a), suggesting that the
phosphorylation of Ago2, rather than the mutation itself, is critical for cell survival under
hypoxia. We did not observe any significant changes between Ago2-WT and Ago2-Y393F
mutant in cell proliferation rate (Fig. 3-40a,b) or anchorage-independent growth (Fig. 340c,d). Interestingly, Ago2-WT but not Ago2-Y393F mutant significantly increased cell
migration in response to hypoxia (Figs. 3-39b, 3-41, 3-42). TKI treatment abrogated Ago2WT-enhanced migration but failed to inhibit Ago2-Y393F mutant cells, indicating that
Ago2-Y393 phosphorylation is important for EGFR-enhanced cell migration under hypoxia.
Similar results were also obtained from three-dimensional invasion assay with or without
TKI treatment (Figs. 3-39c, 3-43). These results demonstrate the functional importance of
Ago2-Y393 phosphorylation in blocking cell apoptosis and enhancing cell invasiveness
under hypoxia.
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Figure 3-38 Y393F mutant Ago2 cells are more susceptible to apoptosis in response to hypoxia.
Apoptosis analysis of HeLa CMV Ago2 stable clones by FACS analysis. Data are shown as mean ±
s.d., n=3. * indicates P<0.05.
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Figure 3-39 Ago2-Y393
Y393 phosphorylation mediates EGFR
EGFR-enhanced
enhanced cell survival and
invasiveness under hypoxia, and significantly correlates with poorer overall survival in breast
cancer patients.
FACS, n=3. b, In vitro migration assay. Result was calculated based
a, Cell apoptosis analyzed by FACS
on five randomly selected fields per membrane in triplicate, n=3. c, In vitro 3-D
D invasion assay,
assay n=5.
d, Representative
epresentative IHC images of pp-Y393-Ago2
Ago2 in human breast tumor and its adjacent normal
tissue. e, Correlation
ation between pp-Y393-Ago2
Ago2 and overall survival in breast cancer patients (n=125).
(
P<0.0001, Kaplan-Meier
Meier survival analysis. All data represent mean ± s.d.; * indicates P<0.05, t test.
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Figure 3-40 Cell proliferation and anchorage-independent cell growth are not significantly
affected by WT or Y393F mutant Ago2.
Cell proliferation was detected by BrdU Cell Proliferation Assay Kit (Cell Signaling). a, 5×103 HeLa
CMV Ago2 stable transfectant cells, b, 2×103 MDA-MB-231 CMV Ago2 stable transfectant cells,
were seeded at 96 well-plates and cultured under normoxia for 24 hr or hypoxia for 24, 48 and 72 hr.
10 µM BrdU was added to the plate and cells were incubated for 4 hr. Data are shown as mean ± s.d.,
n=5. Soft agar colony formation 15 days after culture. c, 1×104 HeLa CMV Ago2 stable transfectant
cells or d, 5×103 MDA-MB-231 CMV Ago2 stable transfectant cells on agarose gel. Colonies that
grew beyond 50 µm in diameter were scored as positive. Colony number was counted based on three
random chosen areas per dish in triplicate. Data are shown as mean ± s.d., n=3.
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Figure 3-41 Ago2-Y393 phosphorylation enhances cell migration under hypoxia, which can be
blocked by Iressa treatment.
Representative photographs of in vitro cell migration assay shown in Figure 3-39b. The average
number of migrated cells per field (counted visually under a light microscope at original
magnification ×200) shown in Figure 3-39b was calculated based on five randomly selected fields
per membrane in triplicate.
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Figure 3-42 Ago2-Y393 phosphorylation enhances cell migration in response to hypoxia.
Top, Representative photographs of in vitro cell migration assay using MDA-MB-231 CMV Ago2
stable clones cultured under normoxia or hypoxia, as indicated. Bottom, corresponding quantitation
data are shown as mean ± s.d., n=3. *indicates P<0.05. The average number of migrated cells per
field (counted visually under a light microscope at original magnification ×200) was calculated based
on five randomly selected fields per membrane in triplicate.
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Figure 3-43 Ago2-Y393 phosphorylation mediates EGFR-enhanced cell invasiveness under
hypoxia.
Representative images of in vitro 3-D invasion assay shown in Figure 3-39c. 9 images were taken by
microscope and merged together to show the whole area (marked by yellow circle) for cell invasion
in each well (each experimental group contained 5 wells as repeats). HeLa-CMV-Ago2-EF1CopGFP stable cells are highlighted by their own GFP fluorescence. The number of invaded cells
was calculated based on the total cell number in each invasion area as marked by yellow circle after
48 hr as indicated.
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3.4.2 Phospho-Y393-Ago2 is specifically enriched in hypoxic primary tumors and
significantly correlates with poorer overall survival in breast cancer patients
Finally, we utilized orthotopic xenograft breast cancer model to establish the
relationship between hypoxia, EGFR, and p-Y393-Ago2, and showed that p-Y393-Ago2
along with EGFR is upregulated during tumor progression and specifically enriched in
hypoxic tumor areas (Fig. 3-44). To further examine the clinical relevance of Ago2-Y393
phosphorylation, we analyzed the expression patterns of p-Y393-Ago2, EGFR, and the
degree of hypoxia (indicated by HIF1α and HIF2α (Bertout et al., 2008)) in primary breast
tumors in consecutive sections collected from 128 human breast cancer patients. In adjacent
normal breast tissues, the expression of p-Y393-Ago2 was low but highly elevated in
hypoxic breast tumors (Fig. 3-39d). We observed significant positive correlations between
p-Y393-Ago2, EGFR, HIF1α and HIF2α (Fig. 3-45a, Table. 3-1) and further validated that
Ago2-Y393 phosphorylation was enriched in hypoxic subareas of breast tumors with
positive expression of EGFR (Fig. 3-45b). Moreover, higher expression of p-Y393-Ago2
correlated significantly with poorer overall survival in breast cancer patients (Fig. 3-39e),
supporting its clinical importance as a potential prognostic marker for breast cancer patient
survival.
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Figure 3-44 The expression of phospho-Y393-Ago2 is upregulated during tumor progression
and specifically enriched in the hypoxic tumor subareas.
a, Top, experimental design for orthotopic breast cancer mouse model using MDA-MB-231 cells
(1×106 cells per mouse). Middle, representative IHC images of consecutive sections from collected
primary tumors (day 8 and day 24). Bottom, quantitative diagrams showing the expression patterns
of EGFR, p-Y393-Ago2 and the degree of hypoxia (based on the average score for hypoxyprobe(Hutchison et al., 2004) and HIF1α) in primary tumors. Data at bottom right are shown as
mean, n=2. Data at bottom left are shown as mean ± s.d. Statistical analyses were performed by
ANOVA or by Student’s t test, n=10 (score was based on tumor sub-areas).

b
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Figure 3-44. The expression of phospho-Y393-Ago2 is upregulated during tumor progression
and specifically enriched in the hypoxic tumor subareas.
b, Primary tumors (mouse xenograft model) collected on Day 8 and Day 24 were fixed and stained
with antibodies against endogenous HIF1α (green), EGFR (magenta), p-Y393-Ago2 (red), and DAPI
(blue).
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Figure 3-45 Phospho-Y393-Ago2 is specifically enriched in human primary breast tumor
hypoxic subareas with positive expression of EGFR.
a, Human primary breast tumors (128 cases) were examined by IHC staining and the positive
correlations between phospho-Y393-Ago2, EGFR and HIF1/2α are shown in Supplementary Table
1. Representative IHC staining images show that the expression of p-Y393-Ago2 was elevated in
hypoxic breast tumor (HIF1/2α positive) with positive expression of EGFR. p-Y393-Ago2 was
hardly detected when HIF1/2α or EGFR was not expressed.
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Figure 3-45 Phospho-Y393-Ago2 is specifically enriched in human primary breast tumor
hypoxic subareas with positive expression of EGFR.
b, Three cases as indicated were chosen to show the colocalization between p-Y393-Ago2, EGFR
and the hypoxic microenvironment (indicated by HIF1α) by immunofluorescence analysis. Breast
tumor samples were fixed and stained with antibodies against endogenous HIF1α (green), EGFR
(magenta), p-Y393-Ago2 (red), and DAPI (blue). S: surrounding tissue; T: human breast tumor area.
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Table 3-1 p-Y393-Ago2 positively correlates with EGFR, HIF1α,
α, HIF2α
α in human
breast carcinoma
p-Y393Ago2
-/+
++
+++
Total
p-Value

-/+

EGFR
++

+++

-/+

HIF1α
++

+++

-/+

HIF2α
++

+++

18(14.1%)

4(3.1%)

3(2.3%)

14(10.9%)

3(2.3%)

9(7.0%)

15(11.7%)

6(4.7%)

5(3.9%)

27(21.1%)

7(5.5%)

8(6.3%)

9(7.0%)

8(6.3%)

19(14.8%)

11(8.6%)

12(9.4%)

14(10.9%)

29(22.7%)

9(7.0%)

23(18%)

13(10.2%)

9(7.0%)

44(34.4%)

11(8.6%)

17(13.3%)

37(28.9%)

74(57.8%)

20(15.6%)

34(26.6%)

36(28.1%)

20(15.6%)

72(56.3%)

37(28.9%)

35(27.3%)

56(43.8%)

P<0.04

P<0.01

P<0.001

Expression patterns of p-Y393-Ago2, EGFR, HIF1α and HIF2α in the consecutive sections
from human breast tumors were determined and summarized. (-/+): negative-low; (++):
positive-medium; (+++): positive-high. The correlation between p-Y393-Ago2, EGFR,
HIF1α and HIF2α was analyzed using SPSS 16.0 Pearson Chi-Square Test. P-value that
less than 0.05 was set as the criterion for statistical significance.
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3.5 Discussion and future directions
In this study, we identified a novel role of EGFR in miRNA maturation via Ago2Y393 phosphorylation. While these results support EGFR as the tyrosine kinase that
suppresses miRNA maturation through Ago2-Y393 phosphorylation under hypoxia, there
may be other tyrosine kinases that can also contribute to phospho-Ago2-mediated miRNA
processing as indicated by Figure 3-32. Additionally, several interesting questions are raised
from our data and need to be further studied in future.
Q1. What is the complete molecular mechanism by which phosphorylated Ago2
affects processing of miRNAs to their mature form? Is it entirely due to a reduction in
phosphorylated Ago2/Dicer interaction?
The steady level of a mature miRNA is control by both biogenesis and turnover. Ago2
regulates miRNA maturation and also stabilizes the mature miRNA after loading into RISC,
enhancing the expression of mature miRNA as a net result. To demonstrate the functional
importance of reduced pAgo2-Dicer interaction, we knocked down endogenous Dicer in
HeLa TetOff inducible Ago2 stable clones to decelerate miRNA maturation under hypoxia.
If reduced mature miRNA expression in WT Ago2 cells is solely caused by suppressed
miRNA maturation through decreased p-Y393-Ago2-Dicer interaction, restriction of their
maturation process by silencing core enzyme Dicer would significantly diminish the
difference of miRNA expression in WT and Y393F Ago2 stable clones. On the other hand,
if it is a consequence of decreased mature miRNA stability (likely due to reduced binding
affinity with p-Y393-Ago2), expression difference of mature miRNAs should not be
affected even after knocking down Dicer. Indeed, after silencing Dicer the expression
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difference in mature miRNAs between WT and Y393F Ago2 was significantly diminished,
suggesting that the maturation of those long-loop mHESM is suppressed by Ago2-Y393
phosphorylation through Dicer, which in turn contributes to the decreased level of mature
long-loop mHESM in WT Ago2 cells. Moreover, silencing Dicer diminished the loading
difference between WT and Y393F Ago2 under hypoxia. This result suggests that enhanced
precursor loading of Y393F Ago2 was largely due to its increased association with Dicer.
Correspondingly, more mature long-loop mHESM were loaded onto Y393F-Ago2,
consistent with its enhanced RISC activity as indicated by luciferase reporter assay.
However, the mature miRNA loading difference between WT and Y393F Ago2 was Dicerdependent and similar to the one we observed in mature miRNA expression. Therefore,
reduced mature miRNA loading of WT Ago2 could be a consequence of suppressed mature
miRNA expression. Nonetheless, the potential contribution from pAgo2-mediated miRNA
stability control cannot be completely excluded. To fully address this issue, we need to
perform in vitro small RNA loading assay to see whether Ago2’s binding affinity towards
long-loop mHESM or other short-loop miRNAs is altered by phosphorylation at Y393.
Q2. How does the long-loop structure of miRNAs contribute to the selective
targeting by EGFR? Is Ago2 the only downstream target of EGFR involving in miRNA
regulation in response to hypoxia?
The structure of miRNA precursors that selectively targeted by EGFR in response to
hypoxia was shown in Figure 3-28. The majority of mHESM that are also regulated by
Ago2-Y393 phosphorylation do have a long-loop structure in their precursors and we
already showed that the long-loop structure is required and sufficient for phospho-Y393Ago2-mediated suppression on miRNA maturation under hypoxia. However, other mHESM
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(not affected by Ago2-Y393 phosphorylation), lacking the long-loop structure in their
precursors were regulated by EGFR in response to hypoxia, suggesting that Ago2-Y393
phosphorylation is only one of the major downstream events that responsible for EGFRsuppressed miRNA maturation in response to hypoxia. Also, the long-loop structure in
miRNA precursors is important for p-Y393-Ago2-mediated miRNA regulation but is not
required for the selective targeting by EGFR. Recently, several EGFR-downstream kinases
have been proposed to play a role in miRNA biogenesis pathway, including Erk, which
phosphorylates TRBP to enhance the general miRNA processing but specifically reduce the
expression of let-7 family (Paroo et al., 2009), and AKT3 (Horman et al., 2013), which
phosphorylates Ago2 at Ser387, resulting in enhanced translational repression but reduced
cleavage activity. Nonetheless, whether EGFR has additional direct binding partners
involved in miRNA processing remain unknown and worth to be investigated in future.
Q3. What is the effect of phosphorylated Ago2 on RISC complex formation?
Different from RISC loading complex (which consists of Dicer, TRBP and Ago2
(Chendrimada et al., 2005; Diederichs and Haber, 2007)) involved in miRNA maturation,
RISC complex is responsible for the executing step of miRNA-mediated gene silencing
(Eulalio et al., 2008) and is constituted by many proteins, including Ago2, GW182,
TNRC6A/B/C and etc. RISC complex also associates with 5’ decapping complex, including
Dcp1A, Dcp2 and XRN-1, for miRNA-mediated mRNA destabilization (Parker and Sheth,
2007). In 293T overexpression system, Ago2-GW182 and Ago2-Dcp1A interactions were
slightly affected by Ago2-Y393 phosphorylation (Fig. 3-46). The data itself cannot support
nor exclude the possibility that Ago2-Y393 phosphorylation may affect RISC formation as
multiple proteins were involved in this complex. I believe that this could be an interesting
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direction that worth to be pursued further, since Ago2 is known to be the catalytic core of
RISC and plays essential roles in miRNA-mediated gene silencing.

Figure 3-46 The association between Ago2 and other RISC components is also affected by
Ago2-Y393-phosphorylation.
Protein samples of immunoprecipition are from the same experiment as shown in Figure 3-27. AntiFLAG immunoprecipitates were blotted with GW182 or Dcp1A antibody to show the interactions
between Ago2 and other RISC components.
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Q4. What are the targeted proteins that upregulated by p-Y393-Ago2 due to
suppressed miRNA maturation in response to hypoxia stress?
To address this question, we first screened mRNAs that were affected by EGFR under
hypoxia and were predicted to be targeted by multiple long-loop mHESM. We chose LOX
as an example (Fig. 3-47). First of all, Y393F Ago2, compared with WT, was loaded with
more LOX mRNAs under hypoxia (pink vs. red, Fig. 3-48; RIP input is shown in Fig. 3-25e),
suggesting LOX as a potential target regulated by Ago2-Y393 phosphorylation. Moreover,
the difference between WT and Y393F Ago2 in LOX mRNA loading was significantly
diminished after silencing Dicer (Fig. 3-48), implying that reduced LOX mRNA loading in
WT Ago2 was largely due to suppressed expression of long-loop mHESM. To examine the
readout of targeting repression, we analyzed LOX expression in HeLa CMV Ago2 stable
clones and found that Y393F Ago2 cells expressed lower level of LOX in response to
hypoxia (Fig. 3-49), consistent with its enhanced LOX mRNA loading as shown in figure 348. A similar result was observed in MDA-MB-231 CMV Ago2 stable clones (Fig. 3-50).
Importantly, TKi treatments (1 µM Iressa and 50 nM AG1478 for 24 hr) diminished the
expression difference of LOX between WT and Y393F Ago2 stable clones, indicating that
LOX is regulated by Ago2-Y393 phosphorylation downstream of EGFR activation under
hypoxia. However, LOX is only one of the examples that regulated by phosphorylated Ago2
in response to hypoxia. We believe more endogenous proteins are regulated by Ago2-Y393
phosphorylation, which collectively play important roles in cellular response against
hypoxic stress. To this end, we plan to use non-biased antibody array to explore the profile
of target proteins that are regulated by phospho-Y393-Ago2 under hypoxia. This result will
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help us further understand the functional role of Ago2 phosphorylation in miRNA-mediated
gene slicing, specifically in response to hypoxic stress.

Figure 3-47 The 3’UTR of LOX mRNA are predicted to be targeted by multiple long-loop
mHESM.
Conserved miRNA targeting sites (predicted by TargetScan) are shown as indicated.

Figure 3-48 Ago2-Y393 phosphorylation reduces the loading of LOX mRNA, a process that is
dependent on Dicer.
RIP enrichment of LOX mRNA as indicated. RIP input controls are shown in Figure 3-25e.
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Figure 3-49 LOX is regulated by Ago2-Y393 phosphorylation in response to hypoxia.
Western blot analysis of HeLa Ago2 stable transfectants as indicated. HIF1α and HIF2α are used as
positive controls for cellular hypoxic response. β-actin is used as loading control.

Figure 3-50 EGFR kinase inhibitors diminish the expression difference of LOX in WT and
Y393F Ago2 stable clones under hypoxia.
Western blot analysis of MDA-MB-231 Ago2 stable transfectants as indicated. HIF1α is used as
positive control for cellular hypoxic response. β-actin is used as loading control.
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Q5. What’s the biological function of Ago2-Y393 phosphorylation in primary tumor
growth and metastasis?
To assess the in vivo biological function of Ago2-Y393 phosphorylation, we injected MDAMB-231 parental and Ago2 stable tranfectants, including vector control, WT and Y393F
Ago2, into mouse mammary fat pads, an orthotopic tumor model for breast cancer.
Consistent with in vitro proliferation assays (Fig. 3-40), we didn’t observe significant
difference in primary tumor growth among those experimental groups (Fig. 3-51).
Interestingly, higher frequency of primary tumor relapse as well as distal metastasis (lymph
node metastasis and lung micro-metastasis) was found in WT Ago2 cells after primary
tumor removal for 4 weeks (Figs. 3-51, 3-52), suggesting that Ago2-Y393 phosphorylation
plays a pivotal role in cancer progression. We reasoned that high frequency of primary
tumor relapse could due to enhanced local invasion. Indeed, more WT-Ago2 cells invaded
into the surrounding blood vessels when the primary tumors were removed (Fig. 3-53).
However, the key events downstream of Ago2-Y393 phosphorylation that specifically
contribute to the development of malignancy remain unclear and need to be systemically
investigated in future.
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Figure 3-51 Ago2-Y393 phosphorylation enhances primary tumor relapse while has no
significant effects on primary tumor growth.
a, Representative luminescence images for primary tumors before surgery and tumor relapses after
surgery. b, Primary tumor weight as indicated. c, Percentage of primary tumor relapse in different
groups as indicated. P, parental; V, vector; WT, WT Ago2; MUT, Y393F Ago2.
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Figure 3-52 Ago2-Y393 phosphorylation promotes distal metastasis.
a, Representative HE-staining and MRI images for lymph node metastasis and lung micrometastasis. b, quantification of lymph node metastasis as indicated. c, quantification of lung micrometastasis as indicated. P, parental; V, vector; WT, WT Ago2; MUT, Y393F Ago2.
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Figure 3-53 Ago2-Y393 phosphorylation facilitates tumor cells invading into adjacent blood
vessels.
a, Representative HE-staining images for tumor invasion into adjacent blood vessels. b,
quantification of primary tumor local invasion as indicated. P, parental; V, vector; WT, WT Ago2;
MUT, Y393F Ago2.

Our Proposed Model
Our research work demonstrates EGFR as a novel direct mediator that modulates
miRNA maturation in response to hypoxia through phosphorylation of Ago2 at Tyr393 (Fig.
3-54). This work opens a new direction to further understand the regulation of miRNA
machinery in response to stress signaling, which is likely to have important clinical
implications.
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Figure 3-54 Proposed model for EGFR-regulated miRNA maturation in response to hypoxia
through phosphorylation of Ago2.
E, EGFR; A, Ago2; D, Dicer; T, TRBP; RISC, RNA-Induced Silencing Complex.
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